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Summary 
Tumours show large variations in response to radiotherapy, both across tumour types 
and within individual tumours. One way to counteract radioresistance is to increase the 
radiation dose to resistant regions by so-called biologically adapted therapy. 
Visualisation of these regions based on properties related to radioresistance, such as 
metabolism, hypoxia, proliferation, and vascularisation, can act as basis for target 
definition, and can be obtained by PET/CT, dynamic MRI, and dynamic CT imaging. 
One aim of the present work was to improve tumour visualisation in images 
obtained before and during radiotherapy. An analysis of dynamic FDG-PET (D-PET) 
and dynamic contrast-enhanced CT (DCE-CT) images of three canine patients showed 
similarities between the two image modalities with respect to tumour vascularisation. 
The results indicated that D-PET may be used alone for assessment of both tumour 
perfusion and metabolic activity, simplifying the image acquisition. We also 
investigated a new method for tumour visualisation by use of image subtraction in CE 
cone-beam CT (CE-CBCT) images, obtained during IMRT of one of the dogs. The 
method was shown to be feasible and produced images with a clearly visualised tumour.  
We further aimed to investigate the radiobiological effect of biologically adapted 
dose delivery. An IMRT planning study based on CE-CBCT images of the first canine 
IMRT patient demonstrated that such dose planning was feasible. This approach gave 
the highest effect on the tumour and thus showed that biologically adapted treatment 
was the best choice for this treatment case. Furthermore, a hypoxia dose painting study 
with a highly heterogeneous tumour model, where MLC leaf widths and IMRT 
parameters were varied, indicated that reducing the leaf widths from 10 to 5 or 2.5 mm 
gave increased tumour control probability. We also implemented dose painting by 
contours in an anthropomorphic phantom. An optimal dose delivery was not achieved. 
In conclusion, dynamic FDG-PET before radiotherapy and CE-CBCT during 
radiotherapy may be valuable. Dose painting should preferably be delivered by MLCs 
with small leaf widths. However, a high radiobiological effect from high-resolution 
dose painting could not be demonstrated in practice. An alternative dose painting 
approach or treatment modality may thus be required for biologically adapted dose 
delivery to highly heterogeneous tumours. 
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1. Introduction 
Solid tumours are heterogeneous and structurally complex with respect to factors like 
blood flow, oxygen and nutrient supply, cell growth, cell density, pH, and bioenergetic 
status.1, 2 These biological factors are primarily created by inadequate and 
heterogeneous vascular networks, and give rise to a variable resistance to nonsurgical 
treatments like chemotherapy and radiotherapy. The variability in such resistance 
factors exists both between and within tumour types, between different parts of the 
tumour, and may also change with time. 
Radioresistant cells within a tumour may cause recurrent growth and thus lack of 
local control following therapy.3-5 It has therefore been suggested to apply 
heterogeneous tumour dose distributions in accordance with the spatial and temporal 
variation of radiosensitivity, so-called biologically adapted radiotherapy.6-14 To guide 
such focal dose escalation, a radioresistance map of the tumour is required. One strategy 
to obtain such a map is through noninvasive biological imaging.  
Biological imaging includes molecular imaging, which deals with the cellular 
and sub cellular biological processes, and functional imaging, which focuses on 
physiological activities within a certain tissue.15, 16 Advances in these modalities may 
improve our ability to depict targets which may reflect the radioresistance of the 
tumour. Through functional imaging with computed tomography (CT), magnetic 
resonance imaging (MRI), and positron emission tomography (PET) one can visualise 
factors like vasculature, proliferation, hypoxia, and metabolism.17 These characteristics 
may serve as guidance maps for focal dose escalations in radiotherapy. Assessment of 
such factors before, during and after treatment is thus important to tailor personalised 
treatment regimens.18 It is still a matter of discussion, however, how to best incorporate 
this information into radiotherapy and the literature shows that there is high interest in 
this field.19 
Technological developments in radiotherapy, such as inverse treatment planning 
algorithms, intensity modulated radiotherapy (IMRT), and multileaf collimators 
(MLCs) with increased resolution and accuracy have enabled high gradient, 
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heterogeneous dose distributions in the patient. Such achievements have therefore been 
a premise for implementing focal dose escalation. The width of the MLC leafs 
influences the obtainable resolution of the dose distributions, and has been widely 
investigated in modelling studies.19, 20 Data concerning biological effect evaluations for 
various leaf widths are still scarce, though, and the optimal resolution for biologically 
adapted therapy is yet to be decided.21 
Cone-beam CT (CBCT) has been integrated with the linear accelerator for 
volumetric imaging in the therapy room, and has contributed highly to the development 
of image guided radiotherapy (IGRT). Visualisation of tumour related changes during 
treatment is of great interest for treatment setup and monitoring. Still, soft tissue 
components may be hard to separate in cone-beam CT images. Improving tumour to 
background contrast in cone-beam imaging may be advantageous in biologically 
adapted radiotherapy.  
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2. Aims 
The overall aims of this study were to improve tumour visualisation and to investigate 
the radiobiological effect of biologically adaptive dose delivery. 
 
Specific aims were to:  
x Compare early uptake patterns obtained by dynamic 18F-fluoro-2-
deoxyglucose (FDG) PET and dynamic contrast-enhanced CT (DCE-CT) 
imaging (paper I). 
 
x Investigate the feasibility of using contrast-enhanced CBCT (CE-CBCT) 
to visualise the tumour before and during treatment, and evaluate 
different treatment adaptation strategies based on such visualisation 
(paper II and III). 
 
x Analyse the effect of radiotherapy planning with different MLC leaf 
widths and investigate the delivery of biologically adapted heterogeneous 
dose distributions to an anthropomorphic phantom (paper IV and V). 
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3. Background 
3.1. Cancer 
Tumour and neoplasm are collective terms denoting an abnormal mass of tissue 
resulting when cells with changed or damaged genetic material (DNA) begin to grow 
without control.22 Cells from benign tumours do not spread to other parts of the body, 
and can often be removed without coming back, they are not cancerous. Malignant 
tumours, however, are cancerous, and lead to significant morbidity and mortality. They 
grow into surrounding normal tissues and metastasise to vital organs throughout the 
body.23 Such distant spread of tumour cells is the cause of 90% of human cancer 
deaths.24, 25 It has been proposed that the genetic characteristics, or genotypes, of cancer 
cells are manifested in six essential alterations in the cell physiology, acquired during 
tumour development: self-sufficiency in growth signals, insensitivity to antigrowth 
signals, evasion of programmed cell death, or apoptosis, unlimited growth potential, 
sustained blood vessel growth, and tissue invasion and metastasis.25 Later progress has 
further added two emerging hallmarks to this list; reprogramming of energy metabolism 
and evading immune destruction (Fig. 1).26 There are more than 100 different cancer 
types, usually named by the body site where they originated.27 Some cancers start in 
blood cells and do not give rise to tumours, while cancers arising from organs and solid 
tissues become solid tumours. The latter represents more than 90% of all human 
cancers.22, 23 
Among the 4,9 million inhabitants in Norway, there were registered 27 520 new 
cancer cases in 2009 (0.6%), and 10 600 patients received external radiotherapy.28 A 
total of 200 000 persons had cancer in 2009 (4%), and the probability of developing 
cancer before the age of 75 is 28% in women and 35% in men.29 The cancer incidence 
in Norway has been increasing since population-based cancer surveys were initiated. In 
the period 2004-2009 the general increase in incidence was 1.8% per year, but the 
number varies highly between cancer types. The five-year survival also varies much 
between cancer types and was around 14% for lung cancers, 63% for colon and rectum 
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cancers and 87% for prostate and breast cancers (2004-2009). These numbers show an 
increase of 2-8% from the previous five year period.  
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Figure 1. The eight hallmarks of cancer. Adapted from Hanahan and Weinberg.26 
 
Tumour vasculature 
To grow beyond a small pool of tumour cells and induce metastatic spread, the cancer 
has to develop its own blood supply.30 This is done by stimulating the growth of 
endothelial cells from surrounding vessels into the tumour, a process known as 
angiogenesis.23 These newly formed blood vessels are highly different from normal 
vasculature. They are irregular and tortuous with branching patterns that feature 
excessive loops, blind ends and arteriolar-venous shunts, and they tend to be more leaky 
(Fig. 2).1 These vessel structures result in disorganised and variable blood flow, making 
the delivery of oxygen and nutrients to the tumour cells less efficient than in normal 
tissues. This leads to acidic, glucose- and oxygen-deprived regions in most tumours.  
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Figure 2. The vascular system in normal tissue (A) and in solid tumour (B).1 
 
Hypoxia 
Normal tissues typically have a median oxygen pressure of 40-60 mmHg (pO2).23 
Tumour tissues with severely reduced oxygen concentration are termed hypoxic. They 
may even be completely depleted of oxygen, i.e. anoxic. Diffusion-limited, or chronic, 
hypoxia increases with distance between the nutritive blood vessel and the tumour cells. 
A distance of more than roughly 50 ȝm can give pO2 values lower than 2.5 mmHg.31 
The cells are still viable, but with increasing distance to the vessel they will eventually 
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die and necrotic tissue will develop. Blood vessels may also be temporarily occluded, 
leading to perfusion-limited O2 delivery. This is often a transient condition and may be 
termed acute hypoxia.32 
It has been shown that 50-60% of locally advanced solid tumours can exhibit 
hypoxic and anoxic regions that are heterogeneously distributed within the tumour 
masses.32 It has also been indicated that hypoxia-adapted cells can proliferate despite 
oxygen or nutrient deprivation.33 This may lead to increased potential for local invasive 
growth and regional and distant spread.2, 31 This hypoxia-driven, malignant progression 
may result in an aggressive and treatment resistant tumour phenotype. 
Canine tumours 
Naturally occurring canine cancers are attractive models in oncology.18 They share 
many features with human cancers, including histological appearance, tumour genetics, 
molecular targets, biological behaviour, and response characteristics to conventional 
therapies.34 Tumours in pet dogs are comparable in size to human tumours, and are 
relatively outbred compared with tumours in small laboratory animals like mice and 
rats. The canine genome also shows closer similarities with human genomes in those 
gene families associated with cancer compared with for example the mouse genome. 
The range of cancers in pet dogs is as diverse as the cancers seen in human patients and 
have the same biological features, including tumour vasculature and hypoxia, metastatic 
capacity, acquired resistance to therapy, and recurrence rate.34 
3.2. Radiobiology 
The use of x-rays for treatment of cancer, and a large number of nonmalignant 
conditions, was started quite immediately after the discovery of x-rays in 1895. It was 
quickly realised, however, that the radiation dose could not be increased indefinitely due 
to the toxic effects to normal tissues. Radiotherapy is therefore beneficial only if the 
tumour response occurs at a total cumulative dose that does not result in severe normal 
tissue complications. This led to the concept of the therapeutic window. This concept 
describes the response of the tumour and normal tissues as a function of cumulative 
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dose for fractionated radiotherapy (Fig. 3). A certain dose difference must exist between 
the two response curves for the treatment to be beneficial. 
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Figure 3. (a) The therapeutic window is large when the response of tumour tissue is 
greater than that of normal tissue. (b) The therapeutic window is small when the 
response is similar. Adapted from Bernier et al.35 
 
Different radiobiological experiments were carried out during the first decades 
of the 20th century, and in the middle of the 1920s these investigations started to have an 
considerable impact on the design of radiotherapy.35 In the 1930s a consensus emerged 
that it was favourable to divide one large single-dose treatment into a series of low-dose 
treatments, known as fractionated radiotherapy. The treatment effect could then be 
achieved with less damage to normal tissues. 20 years later, in 1953, Louis Harold Gray 
showed that the sensitivity of tumour cells to radiation was higher under well-
oxygenated conditions than under hypoxic conditions.36 This time period thus led to the 
identification of the radiobiological factors that influence the response to fractionated 
treatments, known as the four Rs of radiotherapy: Repair, Repopulation, Redistribution 
and Reoxygenation.37 
 10 
Repair 
Normal cells proliferate relatively slowly and have time to repair radiation induced 
DNA damages before replication. Conversely, rapidly proliferating tumour cells may 
undergo DNA replication with unrepaired damages, which can be lethal. Fractionated 
radiotherapy is thus essential for normal tissue repair and contributes to an increased 
therapeutic window when normal tissues proliferate more slowly than the tumour. 
Repopulation 
Tumour cells that survive irradiation may proliferate, or repopulate, which is a negative 
effect from fractionation. Splitting the treatment into many fractions over an extended 
treatment period may further induce accelerated proliferation of the surviving tumour 
cells. This increases the number of cells to be killed and prolonged treatment times may 
therefore reduce the possibility to achieve local control. Sufficient time between 
fractions is anyhow essential for the normal cells to repair sublethal damage, and 4-6 
hours between fractions seems to be an adequate interval. 
Redistribution 
Cells are more resistant to radiation when they are in the S-phase of the cell cycle. Most 
surviving cells will thus be in this phase. Allowing time for these cells to progress into 
another, more sensitive phase and then be irradiated again is therefore an argument for 
fractionated radiotherapy.  
Reoxygenation 
Another beneficial effect of fractionation is the reoxygenation of hypoxic tumour cells. 
After irradiation the hypoxic fraction of tumour cells is increased due to the inactivation 
of the more radiosensitive aerobic cells. Reoxygenation of the hypoxic cells will occur 
after irradiation, however, gradually increasing the tumour radiosensitivity. The 
reoxygenation occurs over a time span from a few hours to several days, depending on 
the underlying mechanisms. 
Altered fractionations 
In conventional fractionation, a fraction dose of 1.8-2.0 Gy is delivered to the tumour 
once a day, five days a week. Many locally advanced diseases cannot be controlled by 
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this regimen and alternative schedules have been derived from laboratory and clinical 
observations made in the 1970s and 1980s.35 These studies showed that giving smaller 
and more frequent fractions allowed for higher total doses without causing increased 
late morbidity in normal tissues. This approach is termed hyperfractionation. 
Many tumours show rapid cell proliferation, which may even be accelerated by 
irradiation. Shortening of the treatment time to counteract this repopulation is thus 
justified and is the rationale behind accelerated fractionation. Accelerated fractionation 
implies a reduced overall treatment time and an increased mean dose per week above 
the 9-10 Gy given in conventional fractionation.37 Both hyperfractionation and 
accelerated fractionation have been shown to give significant survival benefits. For 
example as shown in a large meta-analysis of 6515 patients with head and neck cancers, 
where a survival benefit of 8% was found for hyperfractionation, and 2% for accelerated 
radiotherapy.38 
3.3. Tumour radioresistance 
Due to the heterogeneity in biological factors, cancers show large variations in 
radioresistance and respond differently to radiotherapy. Tumour types like melanoma, 
osteosarcoma and glioblastoma are in general among the radioresistant ones, while 
lymphoma, myeloma and neuroblastoma are among the most radiosensitive37. Different 
types of carcinomas and lung cancers lie in between, but may also be very radioresistant 
in certain cases. Tissue radiosensitivity is determined mainly by three mechanisms; 
intrinsic radioresistance, tumour cell proliferation, and hypoxia.2, 31, 39, 40 Visualisation 
of radioresistant cells based on these processes thus constitutes the principal foundation 
for dose escalation in radiotherapy. 
Intrinsic radioresistance 
Intrinsic radioresistance is a result of the enzymatic repair of double-strand breaks and 
other DNA damage induced by radiation. Tumour cells can show an increased DNA 
repair capacity which will influence the outcome of radiotherapy.40 This is confirmed 
for example by the positive expression of repair enzymes and reduced clinical response 
and survival in cervical cancer.41-43 It is further shown that tumour cell radiosensitivity 
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is a significant and independent prognostic factor for the outcome of radiotherapy for 
cervix and head and neck carcinomas.44-46 Intrinsic radiosensitivity was here measured 
by the survival fraction at 2 Gy in vitro (SF2), i.e. without the influence of hypoxia and 
repopulation effects. 
Homologous recombination (HR) and nonhomologous end joining (NHEJ) are 
two main pathways involved in repair of double strand breaks, and several gene therapy 
strategies have been developed to inhibit such pathways.37 However, DNA therapy has 
not yet gained widespread clinical implementation, as is also the case for other therapies 
based on antibodies targeting repair enzymes. Increasing the irradiation dose by 
hyperfractionation is so far the chosen strategy for overcoming intrinsic radiosensitivity. 
Combinations with chemotherapy have been found beneficial, for example in advanced 
laryngeal cancer.47 
Proliferation 
Tumours with rapid proliferation show high radioresistance due to the increased growth 
between sessions of fractionated radiotherapy. A retrospective review of nearly 500 
head and neck cancers concluded that increased proliferation set in after a certain 
treatment time, 3-4 weeks in the referred case. An increase in total dose of 0.6 Gy per 
day prolonged treatment time was required as compensation.48, 49  
Activation of the epidermal growth factor receptor (EGFR) is one pathway for 
cells to enhance their proliferation in response to radiotherapy or chemotherapy.50 It has 
therefore been proposed to combine radiotherapy with EGFR-targeted cytostatic agents, 
for example cetuximab, to inhibit repopulation and thereby increase the radiation 
response.40, 50 Results from such studies have been promising for tumour control, but 
have also increased normal tissue toxicity. Another approach is accelerated radiotherapy 
which has shown increased loco-regional control in treatment of head and neck cancers, 
and of Burkitt’s lymphoma.38, 47, 50 Chemotherapy in combination with radiotherapy has 
also been shown to give improved survival in primary treatment of head and neck and 
cervix cancers, possibly due to the inhibition of tumour cell repopulation.50 
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Hypoxia 
Radioresistance to electron and photon radiation rapidly increases when pO2 in a 
tumour is reduced below 25-30 mm Hg (Fig. 4).2  
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Figure 4. (Left) Part of a tumour surrounding a capillary. The partial oxygen pressure 
decreases with increasing distance from the capillary. (Right) This reduces the cell kill 
in response to radiation and anticancer drugs. Adapted from Brown.23 
 
The increased radioresistance is caused by two main mechanisms:  
- Reduction of the direct oxygen-enhancement effect, with fewer fixations by 
oxygen of the radiation induced free radicals in the DNA structure. If oxygen is not 
present during irradiation, the damaged molecules can be restored to their original form 
by reaction with H+.44 For most cell types, the oxygen enhancement ratio (OER) for x-
rays is around 3, but may be lower than this at radiation doses below 3 Gy.36, 44  
- The indirect radioresistance is caused by selection of tumour subpopulations 
surviving the hostile hypoxic environment. These clones may have hypoxia-induced 
genetic changes leading to lower apoptotic potential and higher proliferation rate, 
representing a more aggressive tumour type with increased radioresistance.2 
Additionally, hypoxia results in an increase in DNA repair enzymes and radical 
scavengers, also leading to decreased cell death.51 
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It has been shown that hypoxia, measured by polarographic electrodes, is an 
independent prognostic factor which indicates significantly lower loco-regional control 
after radiotherapy of head and neck cancers.52 The same has been shown for uterine 
cervical cancers and soft tissue sarcomas.2, 53 The use of the hypoxia radiosensitiser 
nimorazole in the DAHANCA 5 head and neck study is an example of counteracting the 
direct oxygen-enhancement effect.54 Patients with low plasma osteopontin levels, as a 
marker of low degree of hypoxia, showed significantly improved loco-regional control 
and disease-specific survival.  
The adverse prognostic impact of hypoxia may, however, also be caused by 
increased regional and distant metastatic potential of these tumours.2 It is important to 
note that such properties can not be altered by local doses of radiation. 
3.4. Tumour response modelling 
Tumour control probability  
Radiobiological experiments have demonstrated that the survival of irradiated cells can 
be described by the Linear-Quadratic (LQ) model of cell killing:  
  
 
)1(2 dddd eeS D
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where S is the surviving fraction after a dose d of radiation to a population of cells.37, 55-
57 Į and ȕ characterise the initial slope and curvature, respectively, of the survival curve. 
For a fractionated treatment course with n fractions of dose d each, the expected number 
Ns of surviving, clonogenic cells is thus given by: 
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where N0 is the initial number of clonogenic cells. Cell repopulation rate and the 
reoxygenation effect are here not taken into account. Repopulation may 
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straightforwardly be taken into consideration, however, by adding a ȖT term in the 
exponent, where Ȗ is the repopulation rate and T is the overall treatment time. 
Tumour eradication is only obtained when every single clonogenic cell has been 
eliminated, i.e. when Ns in equation (2) is zero. The probability that no single 
clonogenic cell is present if the mean number of clonogenic cells is Ns can be obtained 
from Poisson statistics: 
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which gives the probability P of the occurrence of exactly y events when the mean 
number of events is NS. The tumour control probability (TCP) corresponds to the 
probability of finding zero surviving cells, i.e. when y = 0: 
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The clinical implication of this formalism may be illustrated by an example of a 
massive tumour reduction from 109 clonogens down to a mean of 4. The surviving 
fraction is here as low as 4·10-9, but the TCP is still only %8.14  e . Increased cell 
killing by a factor 100 reduces the mean number of surviving cells to 0.04, leading to 
TCP = 96%. These examples indicate that eradicating all the cells in a tumour is a 
demanding challenge. The TCP value may be very useful as a relative measure, as for 
example in comparing dose plans and in evaluating the effects of changing parameters 
in plans. The absolute TCP values must be treated with great caution, however, due to 
the lack of clinical data on radiosensitivity and clonogenic cell density.55 
For a tumour with volume V and clonogenic density ȡ0 the probability of not 
finding any surviving clonogens, and thus obtaining tumour control, is from equations 
(2) and (4) given by: 
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From a radiobiological point of view, this equation is fundamental for the 
understanding of tumour response and its influencing factors. It states, for example, that 
the relative importance of the intrinsic radiosensitivity, given by Į and ȕ, is greater than 
that of the clonogenic density, ȡ0.  
In the case of nonuniform dose distributions in the target volume, the tumour 
may be divided into a number of independent subunits. If the tumour consists of N such 
subvolumes, the control probability for a given subvolume is: 
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where Vi is the volume of element i. Vi  may for voxel-wise representation of the tumour 
be considered to be a constant Vvox equal to the voxel volume. Finally, the total cure 
probability is the product of the cure probabilities for each subvolume of the tumour: 
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There is large inter-patient heterogeneity in the intrinsic radiosensitivity of the 
tumour cells, i.e. in the Į values, and this is suggested to be the main cause for clinically 
observed TCP response curves being less steep.55, 56 This inter-patient variation is 
suggested to have a larger impact than the radiosensitivity variations between 
clonogenic cells within each tumour, i.e. the intra-patient variation.55 It is therefore 
warranted to have a population-based TCP, which may be defined as: 
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where g(Į) is the frequency distribution of Į, which may be assumed to follow a 
Gaussian distribution. 
Another concept concerning dose-response relationships in radiotherapy is the 
normal tissue complication probability (NTCP). The NTCP describes the effects on 
normal tissues for partial-volume irradiations and inhomogeneous dose distributions, 
and different models have been proposed for this purpose.37 The concept has, however, 
not been dealt with in the present work and will therefore not be further outlined. 
Equivalent uniform dose 
The concept of equivalent uniform dose (EUD) is relevant when the dose is distributed 
inhomogeneously over the target volume. The formalism converts the inhomogeneous 
dose distribution into a single dose, the EUD, which causes the same radiobiological 
effect when distributed uniformly over the target volume.44, 58 In terms of cell kill, the 
EUD may be defined as: 
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The right-hand side of the equation describes the mean surviving fraction over N voxels, 
where each voxel receives a dose di. The left-hand side describes a situation where all 
voxels have been irradiated with a dose EUD. This gives an equation quadratic in EUD, 
with the physical solution (for EUD>0): 
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While the TCP is a parameter which gives the probability of reaching a certain 
endpoint, i.e. the probability of eradicating the tumour, the EUD gives a dose as output. 
The EUD can thus be compared with for example the prescribed target dose, or a dose 
limit for a risk organ. 
3.5. Medical imaging 
The first clinical images obtained by CT and MRI were taken in 1971 and 1976, 
respectively, and commercial installations of these imaging systems were available a 
few years later.59,60 Parallel to the progress in CT and MRI imaging, the PET was 
developed and clinical use of the first practical PET scanner was published in 1975.61 
The development of radiopharmaceuticals, in particular FDG, contributed heavily to the 
entry of PET imaging into medicine.62 Later, in 2001, a dual mode PET/CT scanner was 
commercially introduced which integrated the PET and CT modalities into one device.63 
CT and MRI have the advantage of high anatomical and temporal resolution, and 
they are supplementary in their visualisation of tissue types. By including contrast 
agents one can also depict tumour perfusion and diffusion into the extravascular, 
extracellular space (EES). Functional information about tumour vasculature can thus be 
obtained. CT and conventional MRI do not map processes like metabolism and 
proliferation, and no information can be obtained about tissue viability.64  
PET imaging has, by contrast, low anatomical resolution, but provides biological 
insights about the tumour tissue, such as metabolism, proliferation and oxygen status. A 
broad range of isotope markers incorporated into biological molecules have been 
developed for PET imaging of these processes, and the modality has become a 
complementary technique to CT and MRI. 
CT 
CT images are constructed on the basis of transmission measurements of a fan-shaped 
x-ray beam which rotates around the patient. The distribution of attenuation coefficients 
within the depicted volume is calculated by means of digital reconstruction algorithms, 
and each element, or pixel, of the CT image is thereby assigned a CT number. The CT 
numbers appear as grey values in the images and are presented in Hounsfield units 
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(HU), which relate the linear attenuation coefficient in each voxel to the attenuation in 
water:  
1000u 
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where ȝ is the linear attenuation coefficient. The CT numbers range from -1000 for air  
up to between 700 and 3000 for different types of bone, with that for water set to 0.65 
In dose planning systems, the patient tissue distribution is represented by a CT 
image series; a three-dimensional (3-D) CT matrix. Accurate photon beam dose 
computational methods rely on knowledge of the electron densities in this matrix.66 
Since the CT numbers bear a linear relationship to the attenuation coefficients, the 
properties in each volume element, or voxel, of the density matrix may be derived from 
the pixel values in the CT images.67 Such density information is not provided by other 
imaging methods like MRI and PET. CT information is therefore essential to dose 
planning when the inhomogeneity of the irradiated medium is taken into account in the 
dose calculations. 
The CT technology has evolved dramatically over the last decade. Helical 
scanners with multi detector rows, which scan continuously while the patient is moved 
through the CT gantry, were introduced in 1998, and in 2004 scanners with acquisition 
of 64 slices per rotation were introduced.68 Such scanners now have a resolution below 
0.5 mm and X-ray tube rotation times down to 0.3 s. These developments also made 
tumour perfusion measurements readily accessible, enabling functional evaluation of 
tissue vascularity through DCE-CT.69 
Following injection of a contrast medium in the patient, DCE-CT applies 
repeated acquisitions of CT images over a selected volume. The changes in tissue 
density over time can then be measured from the distribution of contrast medium in the 
tumour. A contrast enhancement may also be observed from the leakage of contrast 
medium into the extravascular space. This is due to the contrast molecules having a 
relatively low molecular weight, up to 1550 Da for the contrast agents used in the 
present work, and due to tumours often demonstrating increased capillary permeability 
and vascular density over normal tissues. The contrast agents are further both 
hydrophilic and inert and are thus excluded from the intracellular space.  
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The usefulness of DCE-CT within oncology is related to vascularisation and 
tumour hypoxia. The functional information can quantify physiological changes of the 
tumour, which can aid in tissue characterisation, provide prognostic information, and 
produce clearer delineation of tumours, with corresponding benefits for radiotherapy 
planning.30, 69 
MRI 
While CT relies on ionising radiation for image generation, MRI utilises the principles 
of nuclear magnetic resonance (NMR) to generate sectional images. The NMR principle 
involves the interaction of atomic nuclei with imposed magnetic fields, which cause 
radio frequency NMR signals.70 For NMR the atomic nuclei must have a magnetic 
moment and this presupposes a net nuclear spin.  
The most common magnetic nucleus in tissues is the hydrogen nucleus, which is 
a single proton, and diagnostic imaging applications of NMR almost exclusively 
involve the hydrogen atom. Bone has a relatively poor hydrogen concentration and is 
therefore poorly displayed. The hydrogen content in soft tissue molecules yields, in 
contrast, excellent separation of for example water, fat, proteins and carbohydrates. 
These components are not so well separated in CT, and MRI and CT are therefore 
supplementary to each other concerning anatomical imaging. 
The image contrast in MRI is determined by the NMR signal strength, which is 
influenced by the proton density and the T1 and T2 relaxation times. The influence of 
these parameters is determined by the pulse sequence settings, which aim at optimising 
the contrast in the tissue of interest. If the tissue contrast depends on differences in T1 
times, the pulse sequence is termed T1 weighted, while T2 weighted sequences express 
tissue differences in T2 times. 
Analogous to the CT modality, dynamic contrast enhancement is also applicable 
for MRI studies. DCE-MRI is conducted by injecting a paramagnetic contrast agent, for 
example Gd-DTPA, followed by repeated image acquisitions of a selected volume after 
the injection. The temporal changes in tissue contrast can then be measured and 
analysed. As tumour oxygenation is dependent on the vascularisation, this is a proposed 
method for evaluating tumour hypoxia, as for CT.71  
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MR scanners may also provide diffusion weighted imaging and magnetic 
resonance spectroscopy (MRS). Such imaging capabilities are of minor relevance for 
the current work and will not be further outlined here. 
PET 
PET is a nuclear medicine imaging technique that makes use of positron emitting 
isotopes such as 11C, 13N, 15O and 18F. The isotopes are incorporated into biological 
molecules which act as tracers. The tracers have equal or similar chemical forms as 
naturally occurring biological substrates and can be taken up by cells. The emitted 
positrons slow down to thermal equilibrium in the tissue and recombine with electrons. 
This happens in a few picoseconds after emission and results in pairs of 0.511 MeV 
annihilation photons, emitted in opposite, collinear directions and registered in a 360° 
detector array around the patient. The positrons have a mean travelling distance of up to 
1 mm in tissue and together with a small non-co-linearity in the order of 0.25° for the 
annihilation photons, this affects the obtainable spatial resolution of the PET images.70  
PET imaging provides information with high contrast resolution, but is limited 
as a stand alone imaging modality due to its relatively low anatomical resolution.64 
However, the combination of PET and CT into a clinical hybrid PET/CT scanner 
enabled simultaneous functional and structural imaging. Additionally, information from 
the CT scan could now be used for attenuation correction of the PET images. This 
provided correct quantification of tracer uptake in each voxel. Another option which is 
recently introduced is the combination of PET and MRI, but this will not be further 
outlined here. 
The introduction of a faster lutetium oxy-orthosilicate (LSO) scintillator ten 
years ago, with high light output, improved the spatial resolution from around 6.5 to 4 
mm. This also brought down the possible image acquisition times to 5 minutes for a 
whole-body scan.72 The LSO technology has further enabled time-of flight (TOF) 
scanners, which track the time difference between the two annihilation photons and thus 
improves the resolution and signal-to noise ratio. 
As for CT and MRI, dynamic data acquisition is possible also for PET. This is 
performed by the use of list mode (LM) acquisition where all events are registered 
chronologically together with time stamps from the time of tracer injection. The 
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resulting dynamic image series thus include both the wash-in, or perfusion, phase and 
the metabolic phase. After completion of the image acquisition, data from a certain time 
interval can be selected and image reconstruction over that time interval may be 
performed. This allows for 4-D imaging of the temporal and spatial uptake of the tracer. 
As the tracer is distributed via the vascular network, dynamic PET (D-PET) can provide 
measures of tumour vasculature in addition to the active tracer uptake in target cells. 
PET tracers 
There is a large number of tracers available for PET imaging and a selection relevant for 
marking of metabolism, hypoxia and proliferation will be presented.73  
The most widely used and investigated PET tracer is the glucose analogue FDG, 
which utilises the highly increased glucose metabolism in cancer cells.64, 73 FDG is 
taken up by cells and phosphorylated by hexokinase to FDG-6-PO4 (Fig. 5). Unlike the 
normal metabolite glucose-6-PO4, this phosphate can not proceed in the glycolysis and 
is not further metabolised. FDG-6-PO4 therefore accumulates in the cells and allows 
imaging of disease involvement.74 A similar principle exists also for some of the other 
radiotracers described below. FDG uptake in the tumour is linked to aggressiveness, 
resistance to treatment and poor prognosis.64, 75 Still, FDG is not an absolutely specific 
measure for tumour tissue. Other types of tissue also take up FDG, such as 
inflammatory tissue, salivary glands and certain muscles. 
The upregulation of the glucose transporters (GLUTs) and the glycolytic 
hexokinase enzyme (HK-II) in the glycolytic pathway may be induced by the hypoxia-
inducible factor (HIF-1Į). It has therefore been discussed if FDG could serve also as a 
hypoxia marker.76, 77 However, tumour cells can undergo glycolysis followed by 
anaerobic lactic acid fermentation even under aerobic conditions, called the Warburg 
effect.78 It has been shown that FDG is not well suited for assessment of the oxygen 
status of tumours.64, 77, 79 
Several PET tracers are available for imaging of hypoxia, predominantly for 
marking of chronic hypoxia.19, 64 These are mainly 2-nitroimidazole derivates, such as 
18F-fluoromisonidazole (FMISO) and 18F-azomycin-arabinoside (FAZA), which 
accumulate in hypoxic regions by binding to intracellular macromolecules in viable 
cells at low oxygen tensions. 64Cu-methyl-thiosemicarbazone (64Cu-ATSM) also 
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specifically accumulates in a hypoxic microenvironment, through the selective 
reduction of its metal component. Other hypoxia tracers are fluoroerythronitroimidazole 
(FETNIM), fluoroetanidazole (FETA) and the nitroimidazole EF5.73 
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Figure 5. The uptake and accumulation of FDG in cells. Adapted from Heron et al.74 
 
Tumour-cell proliferation can be successfully imaged using 18F-fluorothymidine 
(FLT), which is retained inside the cell. FLT is specifically active during DNA 
synthesis and serves as S-phase marker. FLT PET may thus potentially be used to aid 
the identification of rapidly proliferating tumour subvolumes, and to prospectively 
assess the response to treatment.64 Other proliferation radiotracers are also available, 
such as thymidine, deoxyuridine, methyl-methionine (MET) fluoroethyl-L-thyrosine 
(FET) and choline.73 
All the factors causing increased radioresistance or recurrence of tumour growth 
should be included when defining the target volume for radiotherapy. The anatomically 
defined gross target volume (GTV) from CT and MRI should therefore preferably be 
expanded with a biological target volume (BTV), defined by specific radiotracers in 
PET. This may result in an expanded, reduced or spatially shifted GTV.73   
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SUV 
The standardised uptake value (SUV) is used as a tool, both to supplement visual 
interpretation of tracer uptake in PET images and for semi-quantitative analysis. SUV is 
a dimensionless ratio of 
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where Q is defined as average activity per unit volume. A gnormalizinQ  can be the whole 
body, the contralateral anatomical site, or an organ, for example liver or brain.80 
The reason for the SUV’s popularity has been the need for a reliable 
reproducible measure of uptake. This need stems from intrapatient comparisons during 
therapy monitoring, from interpatient comparisons in the diagnostic process, relating to 
degrees of pathology, and from comparisons of data between institutions.80 The SUV is 
subject to errors, however, and criticism about the methodology has been made.81 
Factors like body composition, length of uptake period, plasma glucose and partial 
volume effects should be considered. 
3.6. Radiotherapy 
Historical overview 
Wilhelm Conrad Röntgen discovered x-rays in 1895 and the first treatment of cancer 
was accomplished less than 60 days later by Emil Grubbé in Chicago.35 He initiated 
clinical radiotherapy by treating an advanced, ulcerated breast cancer in January 1896. 
However, treatments with these low-energy x-rays of 10-50 kV, and later with ortho-
voltage x-rays of 200-500 kV, suffered from several drawbacks. The therapy had low 
penetration power, gave high surface layer doses in healthy tissue, and resulted in 
unwanted high doses in bone. Meanwhile, the discovery of natural radioactivity by 
Henry Becquerel in 1896 and isolation of radium in 1898 by Marie Curie paved the way 
for utilisation of high-energy photons in cancer therapy. Lead-encapsulated radium 
 25 
needles and tubes were applied with a few centimetres of skin distance, and they 
enabled treatments of more deeply seated tumours. Other applications of radium were 
also developed, such as implantation of radium needles directly into the tumours, and 
irradiation via natural body cavities. Such brachytherapy applications are today still 
highly used, but now with sophisticated after loading equipment and a variety of 
radioactive isotopes as radiation sources. 
Parallel to the development of radium therapy, new methods for producing high-
energy radiation were developed. A method for accelerating electrons by means of 
radiofrequency fields was proposed by Gustaf Ising in 1925, and a real life model of a 
50 keV linear accelerator (linac) was demonstrated by Rolf Widerøe four years later.82 
Before and during the Second World War, the microwave technology was developed 
and betatrons and higher energy electron linacs could thus be constructed. The first 
electron linac designed for radiotherapy was introduced at Hammersmith Hospital in 
London in 1953, and three years later there were seven clinical linacs altogether, 
worldwide.82, 83 These high energy treatment beams overcame to a great extent the 
limitations of the low-energy and ortho-voltage x-rays.  
During the last four decades technological progress has led to a significant 
improvement of the local control rates of many tumours, even in patients with locally 
advanced tumours.35 Treatment planning and medical imaging has profited enormously 
from the revolution in computer technology. The functional and anatomical tissue 
properties mapped by CT, MRI and PET have enabled determination of the size and 
location of the tumour. Beam shaping and radiation shielding by MLCs in combination 
with advanced, intensity modulated beam delivery have further improved the possibility 
to maximise the dose to the tumour and minimise the dose to healthy normal tissue. 
Image guidance in radiotherapy has also contributed to this, and has enabled treatment 
monitoring and interactive adaptation of the treatment based on daily assessment of 
changes in tumour volume and response.84 
The conventional linac gantry has an isocentric movement and rotates 360° 
around the patient (Fig. 6). The actual beam producing structure has not changed much 
over time, however, and the same technological principles are used today as in the time 
of early linac history. The later developments in treatment techniques have resulted 
mainly from the digitalisation of the linac control systems and from added equipment. 
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The last decade has also provided alternatives to the conventional x-ray linac design, 
such as the ring concepts of tomotherapy and of Vero, but these will not be outlined 
here. The utilisation of protons and heavy ions in cancer therapy will likewise not be 
described. 
 
 
 
Figure 6. Modern linear accelerator with add-on imaging equipment. Radiation gantry 
and collimator (above the table), volume imaging system x-ray source (to the right) and 
detector (to the left), and electronic portal imaging detector (below the table, partly 
covered). From Elekta AB web pages. 
 
Image registration and fusion 
CT images are the foundation for 3-D dose planning. The planning CT may assume the 
role of an anatomically correct backdrop for the information provided by the MRI and 
PET modalities, which may have inherent image nonlinearity (MRI) or lack of 
anatomical resolution (PET).85 Information from the two latter modalities may be 
included by manually comparison and hand transfer of the data to the planning CT, 
which is time consuming and unlikely to be accurate. The image sets can alternatively 
be fused by a full 3-D image registration. Such image registration is based mainly on 
two methods; landmark registration and intensity-based registration, the latter also 
called maximisation of mutual information.67, 85 
Landmark registration is based on manual segmentation or identification of 
common structures in the two images to be aligned, and is suitable for image sets with 
clearly identifiable anatomical reference points, or markers. The intensity-based 
registration approach is an automatic iteration method. It utilises mutual information in 
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two images to find a similarity measure, which is maximised at the optimal alignment. 
Mutual information is user independent and suitable for images from different 
modalities. The integration of PET and CT into a dual-mode scanner has eliminated 
user-based registration for this modality. There are still pitfalls, however, since the two 
data sets are not acquired simultaneously and with different longitudinal table 
positions.85  
When image registration has been performed, the image sets must be displayed 
in a coherent way to evaluate the relationship between them. A common way is to 
display the information from both images simultaneously as overlays in one image. 
Different methods for this are used, including colour overlay, dynamic alternating 
display, split view and subtracting images (Fig. 7).67 
 
 
 
Figure 7. CT image with colour PET overlay. Two types of split views are shown. 
 
IMRT 
Intensity-modulated radiotherapy (IMRT) allows for the radiation dose to conform more 
precisely to the 3-D shape of the tumour compared to classical 3-D conformal 
radiotherapy (3-D CRT).86, 87 IMRT provides the ability to deliver a high dose to the 
target volume, and at the same time spare normal tissues and critical structures that are 
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partially or fully surrounded by the target, or by a combination of targets (Fig. 8). IMRT 
also allows higher radiation doses to be delivered to regions within the tumour. 
 
 
 
Figure 8. Left posterior view of a head and neck cancer treated with IMRT. The 54 Gy 
isodose (dark yellow) is partly covering the planning target volume (PTV) (blue). The 
isodose surface is wrapped around the spinal cord (purple with orange margin) and the 
larynx (orange). The right and left parotids (brown) are partly spared.  
 
Advanced MLCs were on a broad scale released to the marked in the middle of 
the 1980s. These collimators had leaves of typically 10 mm width, which could be 
moved independently of each other into the treatment field. This facilitated both a more 
conformal shape of the treatment field and modulation of the photon beam intensity. 
IMRT, which was developed a few years earlier, could now be accomplished by 
modulating the intensity of a large number of small beamlets, typically 10x10 mm,  
within the radiation fields.35, 88  
To determine the beamlet weights which achieved, or at least closely 
approximated, the desired dose distribution, inverse treatment planning algorithms were 
developed. Solving the inverse treatment planning problem was based on works from 
the 1980s and is today the most common strategy for IMRT.89, 90 In inverse treatment 
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planning algorithms the desired dose to targets and dose limits of critical structures are 
defined as a basis, and intensity-modulated beam arrangements are derived to 
acceptably meet these desired dose objectives.87 This is in contrast to forward planning 
algorithms, which have the treatment beams as a starting point. Commonly, the iterative 
inverse planning process is driven by the minimisation of a composite objective 
function, formed by weighting together the dose volume objectives, while fulfilling the 
dose volume constraints for the critical structures in a better and better way along the 
optimisation process.91 By using a sequencer, the beamlets may be grouped together in 
typically 50 fields or more to assure a more efficient and faster delivery of the 
treatment.  
IMRT may be delivered in different ways, but the main distinction is made 
between static and dynamic delivery. If the MLC leaves move during beam delivery, the 
treatment is referred to as dynamic, or sliding window.87 If the beam is turned off 
between each change of the collimator setting, the delivery is termed step-and-shoot. 
Typically 7-12 beam directions, or gantry angels, are used for implementing an IMRT 
plan.88 The beam may also be on during rotation of the gantry. This modality is then 
called volumetric modulated arc therapy (VMAT). The term intensity modulated arc 
therapy (IMAT) is also used.  
MLCs with leaf widths down to 1.6 mm have been developed to increase the 
resolution of the treatment field. Some of these MLC types are add-on equipment 
introducing smaller maximum field sizes, while others are standard, full field 
collimators. 
Dose painting 
As described in chapter 3.3, radioresistance may be heterogeneously distributed within 
the tumour. The radioresistant regions may be targeted by integrating biological 
information into the inverse planning of IMRT. Different studies have suggested that 
molecular and functional imaging could form the basis for selective boosting of tumour 
subvolumes.6, 8, 85, 92, 93 This procedure is called dose painting and strives to tailor the 
exact dose distribution needed for eradication of all tumour cells.6, 7, 73, 88, 94 The benefit 
of this approach was shown by mathematical modelling more than 20 years ago, and 
later modelling studies of the dose painting concept have estimated large gains in 
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tumour control probabilities and improvements in dose distributions within the tumour 
volume.9-14  
Planning for dose painting starts with segmentation of target volumes and organs 
at risk. These definitions are made on bases of CT images in combination with 
functional imaging, depicting biological processes in the tumour tissue that influence 
radiosensitivity (Fig. 9). Such imaging modalities may be PET, DCE-MRI, DCE-CT, 
and MRI spectroscopy.7 Two different dose painting approaches have been proposed. 
Dose painting by contours (DPBC) prescribes a global dose objective inside the 
biological image-based contours, where the intention is to reach a certain dose value 
within the given target.6, 8 Dose painting by numbers (DPBN), or dose painting by voxel 
intensity, prescribes the dose inside the target for each voxel as a function of the signal 
intensity of that voxel in the biological image (Fig. 10).7, 9  
 
 
 
Figure 9. Imaging paradigm in radiation oncology integrating different functional 
imaging modalities (panel A-D) with CT defined GTV (panel E) to obtain a combined 
BTV (panel F).73 
 
 31 
 
 
Figure 10. (A) Anatomical PTV. (B) Biological PTV. (C) Fusion of (A) and (B).  
(D) contour based dose painting. (E) voxel-intensity based dose painting.88 
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The dose prescriptions in dose painting are also differentiated in two strategies; 
dose escalation and dose redistribution. Dose escalation applies additional dose to the 
radioresistant subvolumes of the tumour.95, 96 Dose redistribution increases the dose to 
the radioresistant parts while reducing the dose to the rest of the tumour, keeping the 
mean dose constant.95-97 
Commercial treatment planning systems generally use dose-volume parameters 
to prescribe the desired dose distribution. This is not compatible with the DPBN 
approach, which uses voxel-based dose optimisation, and research treatment planning 
software has so far been a prerequisite for true DPBN planning.98-100 However, the 
DPBC formalism may approach the DPBN formalism by increasing the number of 
contour levels.21, 98 This makes planning for simplified DPBN feasible using an ordinary 
dose planning system, yet making optimisation and evaluation cumbersome as the 
number of volumes increases. In any case, a relationship between the biologically based 
voxel intensities and prescribed doses has to be established.98, 99  
An inherent limitation in the resolution of the delivered dose distribution is 
caused by the application of photons as radiation source. The lateral scattering range 
and accompanying energy deposition several millimetres away from the interaction 
point inevitably restricts the obtainable steepness of the dose gradients. 
The clinical value of dose painting has not yet been proven by appropriate 
trials.88, 101 A few focal dose escalation studies have shown, however, that the treatments 
are well tolerated and do not increase normal tissue toxicity.102, 103 There are a number 
of uncertainties and unknown factors which reside mainly in insufficient knowledge 
regarding the biological meaning of functional imaging, the predictive value of a given 
imaging parameter for radioresistance, and the uncertainties in the transformation of 
radiobiological factors to desired dose and dose constraints.88, 98, 104 Another issue which 
have received little attention so far, is how well the treatment planning systems can 
deliver appropriate dose plans for dose painting objectives and the accuracy of such 
treatment deliveries.21  
Due to the large dose gradients arising when prescribing focal dose escalation, 
one may further expect that high resolution MLCs will be a prerequisite. This is an issue 
which has received little attention in the literature so far.21 MLC leaf width may be an 
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issue for effective treatment delivery in biologically adapted therapy and the problem 
should now be addressed. 
In-room imaging systems 
Developments in medical imaging have increased the ability to localise the target for 
precise administration of radiation. This is advantageous not only for designing 
treatment plans, but also for localisation of the target, the target motion, and the target 
changes during treatment. During the last decade the development within in-room 
imaging has moved from electronic portal imaging devices (EPIDs) towards volumetric 
patient imaging. For conventional linac designs, excluding tomotherapy and Vero, there 
are currently two main solutions for this; in-room CT, or CT-on-rails, and cone-beam 
CT.105  
In-room CT is an integration of a CT-scanner in the linac treatment room, 
enabling imaging of diagnostic quality with the patient positioned on the treatment 
table. Imaging and treatment isocentres are not coincident, however, and the patient has 
to be transported on the treatment table between the two modalities.  
CBCT systems perform tomographic reconstruction from a series of two-
dimensional (planar) radiographs obtained by one half or one full rotation of the x-ray 
source around the patient. Due to the use of a cone-shaped beam and a large area flat 
panel detector, the whole longitudinal imaging volume of the patient is registered 
simultaneously (Fig. 11). This eliminates the need for a longitudinal movement of the 
patient during imaging. The image resolution is good, but the elevated levels of 
scattered radiation into the imaging system cause reduced image contrast compared to 
conventional CT systems.  
Two main systems are in use for CBCT imaging. Kilovoltage (kV) cone-beam 
systems use a conventional CT x-ray generator as radiation source. This add-on system 
operates at a 90° angle with the treatment beam and introduces thereby sub optimal 
mechanical precision. Megavoltage (MV) cone-beam systems use the treatment beam 
for imaging. The imaging system is then in-line with the treatment system and has in 
principle identical isocentres. Artefacts from structures of high atomic number in the 
patient are avoided due to the high energy, and the images can in principle also be used 
for reconstruction of delivered doses. However, the MV beam energy causes low image 
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contrast compared with kV imaging and this may bring along higher radiation doses to 
obtain acceptable image quality.  
 
 
Figure 11. (Left) Fan-shaped, conventional CT. (Right) CBCT. 
 
The reduced soft tissue contrast in the CBCT images hinders the utilisation of 
this application for biologically adapted therapy. Soft tissue tumours may not be 
visualised and this prevents tumour based image guiding and treatment monitoring. 
Improved tumour visibility would thus give benefits with regard to setup accuracy and 
tracking of target changes during treatment. 
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4. Methods and design 
This section describes briefly some aspects of the experimental procedures applied in 
the present work. More detailed descriptions and literature references can be found in 
the original papers. 
4.1. Canine patients, imaging and treatment 
Paper I-III include PET/CT imaging and radiotherapy of three canine patients. These 
patients were companion dogs with naturally occurring head and neck cancers and the 
treatments were performed with curative intent. A brief summary of the patients and 
tumour characteristics is given in Table I. None of the dogs showed evidence of distant 
metastases at the time of diagnosis. The patients were included in a study approved by 
the Norwegian Animal Research Authority (NARA), and written informed consents 
were obtained from the owners. 
 
Table I. Canine patients included in the study. 
 
Patient 
ID 
 
Patient 
breed 
 
Gender* 
 
Weig
ht 
[kg] 
 
Tumour 
location 
 
Tumour 
histology 
Initial 
tumour 
volume 
[cm3] 
 
Paper 
A 
Border 
collie 
F 24 
Right 
maxilla 
Plasma cell 
tumour 
14 
 
I, II, III 
B 
Norwegian 
buhund 
F 16 
Right nasal 
cavity 
Adeno-
carcinoma 
25 
 
I 
C 
German 
shepherd 
M 36 
Left 
maxilla 
Fibrosarcoma 65 
 
I 
* F: intact female, M: intact male 
 
The patients were all given IMRT in treatment series of 10 fractions, one 
fraction a day. At five out of these treatments, CE-CBCT was performed (Fig. 12). 
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Dynamic and static PET/CT imaging was further performed before, during, and after the 
treatment series, and DCE-CT was performed before and after the treatment series.  
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Figure 12. Treatment and imaging schedule for the three canine patients. Day labels are 
indicative only, since there were variations between the patients. PET labels include 
dynamic and static PET. 
 
The three patients were given five fields IMRT with 6 MV photon energy. The 
treatments were planned using the Siemens VSIM virtual simulator (v 2.2) and KonRad 
inverse planning model (v 2.2.18) for patient A and B, and Nucletron Oncentra 
Masterplan (v 3.3) for patient C. The mean fraction dose to the GTV was 4.6 Gy for 
patient A and 4.7 Gy for patients B and C. The treatment machine was an Elekta 
Synergy linear accelerator, equipped with an XVI CBCT system. The dogs were placed 
in prone position on a vacuum cushion in a polymethyl methacrylate (PMMA) case. 
The upper jaws were fixed by a dental form to the PMMA case.  
CE-CBCT imaging were performed prior to the IMRT at the sessions indicated 
(Fig. 12). The metabolic tumour status was monitored by dynamic and static PET 
imaging at day zero, which took place four days before the first treatment. Further PET 
sessions were set at fraction five of the IMRT and around two weeks after the last 
fraction. For patient B and C, a follow up PET examination was performed 3-4 months 
after the treatment. For patient A this PET scan was not implemented due to medical 
complications of the patient. DCE-CT was performed together with the PET imaging at 
the sessions before and after the treatment series.  
PET/CT and DCE-CT imaging was done at a Siemens Biograph 16 scanner. 
Briefly, the imaging procedure started with administration of FDG with an activity of 6 
MBq/kg, using a manual syringe. The scan duration for D-PET imaging was 45 
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minutes. Subsequently, when DCE-CT was included, 10 minutes of DCE-CT imaging 
was performed with the administration of 600-640 mg/kg Omnipaque (iohexol) for 
patient A and 600-640 mg/kg Visipaque (iodixanol) for patient B and C, at a 
concentration of 300 mg/ml. The imaging sessions were concluded with a whole body 
PET/CT, with an acquisition time of three minutes per bed. 
Imaging and treatments were performed under general anaesthesia. At fraction 
five, the PET examination was done prior to the treatment session, with the patients 
kept continuously sedated till the end of the IMRT. DCE-CT was not performed at this 
session due to the possible toxic renal effects from the contrast agent. 
4.2. The heterogeneous tumour model 
The studies in paper IV and V utilised a previously established tumour model, based on 
a female canine patient with a spontaneous osteosarcoma in the nasal region. The gross 
target volume (GTV) was outlined in Gd-DTPA contrast-enhanced MR images. Uptake 
of tracer in the tumour tissue depends on blood flow, vascular density and extra vascular 
space. It has been suggested that these parameters may be related to hypoxia, and the 
MR tracer concentration thus served as a tentative marker for the partial pressure of 
oxygen.51 The tumour was segmented into four compartments based on the tissue 
contrast concentration, and the compartments were in this way related to varying 
degrees of hypoxia. Due to the variation in vascularisation and distribution of tracer 
throughout the tumour, the four tumour compartments appeared highly heterogeneous 
and were partly split up into minor subvolumes. The model therefore represented an 
advanced and highly challenging prescription basis for IMRT. 
IMRT planning 
In paper IV the IMRT planning was done using the VSIM and KonRad systems. The 
MR images containing the compartmental information had previously been converted to 
CT DICOM standard and scaled to have a water-like composition with CT numbers 
around zero. The images were imported to the VSIM virtual simulator and the four 
compartments of the tumour model were defined by a manual contouring procedure in 
the VSIM module. For the IMRT planning, three different types of MLCs were 
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available, with leaf widths of 2.5, 5, and 10 mm. These MLCs represented real, 
commercially available hardware solutions. 
In paper V another MLC was used. This was a BrainLab m3 micro MLC with 
3.0 mm leaf width in the central part of the field, and 4.5 and 5.5 mm leafs laterally. A 
dedicated BrainLab iPlan Dose treatment planning system (v 3.0.2) was used for IMRT 
planning. The MLC is physically installed at one of our linacs, being in clinical use for 
stereotactic treatments.  
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5. Summary of results 
5.1. Paper I 
This paper investigated the resemblance in early tumour uptake patterns of a CT 
contrast agent and FDG PET tracer for three dogs with spontaneous head and neck 
tumours. DCE-CT and D-PET imaging were performed at two sessions. The first 
session was carried out four days before start of the fractionated radiotherapy. The 
second session was performed two weeks after end of treatment for patient A, four 
months after for patient B, and three months after for patient C (Fig. 12). Software tools 
were developed for downsampling the CT image series to the PET image dimensions, 
for segmentation of tracer uptake pattern in the tumours and for spatiotemporal 
correlation analysis of the images. 
The analysis showed that DCE-CT images taken one minute post injection 
qualitatively resembled the D-PET images at all sessions, with the possible exception of 
session two for patient C where little uptake was seen in either image. Segmentation by 
region growing gave similar tumour extension in both modalities and a relatively high 
correlation was found between temporal uptake patterns from DCE-CT and D-PET. The 
heterogeneity in tumour uptake was not significantly different for the two modalities.  
One could therefore conclude that early uptake patterns in tumours assessed by 
DCE-CT and D-PET gave similar results. Using D-PET alone for assessing both tumour 
perfusion and metabolic activity may thus be considered. 
5.2. Paper II 
This paper describes a feasibility study of a canine patient where the goal was to utilise 
contrast enhancement to visualise a soft tissue tumour on CBCT images. At five out of 
10 fractions of IMRT, CBCT imaging was performed before and after administration of 
an iodinated contrast agent. Axial CBCT images were reconstructed and the pre-contrast 
images were subtracted from the post-contrast images. The subtraction images were 
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then over-laid on the pre-contrast images to visualise the contrast enhancement in an 
anatomical reference frame. For comparison, the same procedure was performed on 
DCE-CT images obtained at the PET/CT scanner. 
The procedure produced a clearly visualised tumour in the CE-CBCT images for 
all five treatment sessions. A significant increase in contrast enhancement of 5.2 HU per 
treatment fraction was found. Further, a comparison of overlays for CE-CBCT, DCE-
CT and PET/CT showed that the tumour extent and orientation appeared similar in the 
respective images.  
CE-CBCT imaging was thus shown to be feasible and may be useful for 
online/offline setup corrections. This may be utilised separately or in combination with 
bony anatomy co-registration. Monitoring biological and spatial changes of the tumour 
is facilitated, which enables tumour boosting based on CBCT images. 
5.3. Paper III 
Paper three assessed the therapeutic gain in using tumour co-registration in favour of 
bony anatomy co-registration for setup corrections. Patient setup corrections with 
CBCT imaging have traditionally been based on bony anatomy co-registration. These 
corrections should ideally, however, be based on tumour localisation since the spatial 
relationship between the tumour and bony anatomy may change over the course of 
treatment.  
In this paper, CE-CBCT images from five out of ten treatments of a canine 
patient were used to delineate gross tumour volumes (GTVs) for the purpose of 
radiotherapy adaptation. IMRT dose plans were generated on the basis of these 
delineations and different adaptation strategies were explored. The study showed that 
fully adapted dose planning, based on each CE-CBCT image series, gave EUDs closest 
to the prescription dose and the highest TCP.  
Two other adaptive strategies were investigated, where dose planning was based 
on images acquired at the first treatment session. Patient repositioning was here 
performed either by bony anatomy co-registration, or by co-registration of the contrast 
enhanced images for the two strategies, respectively. These strategies gave EUDs and 
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TCPs close, but inferior, to the first strategy. A fourth approach, with no treatment 
adaptation or patient reposition, was clearly inferior to the other strategies. 
This study showed that treatment adaptation based on CE-CBCT imaging was 
feasible and may lead to improved treatment outcome. An even higher benefit is 
expected in cases with soft tissue tumours showing larger changes in tumour position 
relative to bone and greater deformation than in the present study, where the tumour 
was partly located in bone.  
5.4. Paper IV 
This study aimed at exploring hypoxia dose painting by varying MLC leaf widths and 
IMRT parameter settings. Three different MLC leaf widths of 2.5, 5, and 10 mm and 
four different field arrangements were used, each optimised with four different step-
and-shoot intensity levels. The seven fields/seven intensity levels plan was studied in 
more detail than the others, representing a commonly used parameter configuration. 
Reducing the leaf widths increased the total TCP for all field arrangements. The 
effect on the total tumour control was generally larger when reducing from 10 to 5 mm 
leaf widths compared to reducing from 5 to 2.5 mm. For the seven fields/seven intensity 
levels plan, the TCP increase was most pronounced for the most hypoxic compartments. 
Increasing the number of fields generally also increased the TCP, while there were only 
minor effects on TCP by increasing the intensity levels above five. 
Introducing systematic and random setup errors for the seven fields/seven 
intensity levels plan reduced the total TCP. When the errors exceeded 5 mm there were 
no longer any differences between the MLC types. When exceeding 7 mm setup errors 
there were only small differences in TCP between the redistributed and uniform 
treatment plans. 
The current study indicated that reduced leaf widths are required for highly 
heterogeneous, biologically adapted radiotherapy. To achieve increased probability of 
cure, however, accurate patient setup is a crucial factor. 
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5.5. Paper V 
The purpose of this work was to evaluate the radiobiological effects of planned and 
delivered high resolution IMRT, using dosimetric and radiobiological measures. A 
previously established tumour model with highly heterogeneous oxygen distribution 
was used as a clinical basis, virtually integrated into an anthropomorphic phantom head. 
A micro MLC with 3 mm minimum leaf width was used and the dose distributions were 
measured with Kodak EDR2 films in two planes. The dose planning was based on the 
principle of dose redistribution and three treatments were given. 
The planned dose distributions appeared qualitatively conformal to the 
prescription, but the dose plan compartmental EUD values showed large reductions 
compared to the prescription. The deviation increased with increasing degree of 
hypoxia, with a maximum EUD reduction of 34% for the most hypoxic compartment in 
the caudal plane. The films showed high relative spatial accordance with the dose plan, 
demonstrated by low Ȗ values in the Ȗ analyses. The absolute compartmental mean 
doses for the films were 4-11% lower than expected from the planning, possibly due to 
errors in dose plan output factors for the smallest leaf openings. 
The dose volume based IMRT could therefore not produce an optimal dose 
distribution for the highly heterogeneous tumour presented. Still, the biologically 
adapted radiotherapy was delivered with high precision according to the dose plan. 
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6. Discussion 
Radioresistance in solid tumours have been counteracted by altering the radiotherapy 
schemes into hyperfractionated and accelerated schedules, and by combining with 
chemotherapeutics. In the current project, however, another approach has been 
investigated, namely dose painting and tumour visualisation before and during 
radiotherapy. The results may be of relevance for the definition of target volumes and 
for the implementation of dose escalation in biologically adapted radiotherapy. 
Increase in tumour control and reduction of normal tissue adverse effects are the 
primary goals in radiotherapy research. Crucial factors have been the evolution of 
diagnostic tools and treatment techniques, and the increased knowledge in radiobiology. 
The progress made in CT, MRI, and PET imaging has enabled assessment of 
radioresistant tumour regions, and the development of treatment modalities like IMRT 
and VMAT has facilitated dose painting delivery. 
Dose painting strategies puts stringent demands on spatial accuracy, both in the 
definition of target volume, in the assessment of radioresistant regions and in the quality 
control of treatment delivery. The latter was addressed in our work regarding adaptive 
therapy based on CE-CBCT (paper III), in the investigations of the influence of MLC 
leaf widths on biologically adapted IMRT plans (paper IV), and in the dosimetric 
verification of such plans (paper V).  
IGRT procedures are crucial to ensure spatially correct dose deposition, both for 
conventional radiotherapy and for dose painting. The feasibility study of CE-CBCT 
(paper II) showed a novel application of the CBCT modality, which may be included in 
IGRT procedures. Using CE-CBCT during therapy may also enable monitoring of 
functional and anatomical tumour changes. This allows for treatment scheme 
adjustments in accordance with the functional and anatomical changes of the tumour. 
However, quantifying such alterations presupposes assessment of the functional and 
biological tumour properties prior to treatment. This aspect was addressed in the current 
work (papers I and II), demonstrating overlapping information from DCE-CT and D-
PET. 
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6.1. Comparison of DCE-CT and D-PET 
DCE-CT and D-PET are modalities that can provide information about tumour biology. 
It is, however, unclear whether the same or complementary information is acquired by 
the two methods. The initial distribution phase of CT contrast agent and PET tracer in 
the tumour are in principle analogous processes. The study of the three canine patients 
in paper I indicated that D-PET provided much of the same information and may be an 
alternative to DCE-CT. Contrast-induced nephropathy (CIN), diabetes, reduced renal 
function, and old age are among the risk factors for injection of iodinated CT contrast 
agents, and D-PET may be preferable for patients with such risk factors. The reduction 
of radiation exposure of the patient may also be a motivation for using D-PET rather 
than DCE-CT. Another advantage of PET is the combined imaging of vasculature, 
perfusion, and functional processes like metabolism, proliferation and hypoxia in one 
single uptake session. This can be particularly important for assessment of 
radioresistance. 
There are, however, some restrictions in using D-PET rather than DCE-CT for 
treatment planning. One such limitation is the reduced spatial resolution of PET images 
compared to CT images. High-resolution DCE-CT images have been shown to correlate 
with the spatial distribution of blood vessel density in mouse models, and the high 
image resolution in CT may thus be a prerequisite for optimal application of dose 
painting.106 Further, the intra-tumour heterogeneity in the current project (paper I) was 
reduced two- to three-fold when the CT images were re-sampled to PET resolution 
level. Such a reduction may lead to loss of information of the true biological tumour 
variations. This can have consequences for treatment efficacy and for treatment 
outcome prediction. Further studies are needed where these issues are addressed. 
Another disadvantage of the D-PET modality is the increased occupation time of 
the scanner, which will be doubled compared with ordinary PET examinations. An 
exception is the first time slot in the morning, where the scanner is normally left unused 
for about one hour due to the rest period after the first tracer injection. Using D-PET on 
a larger scale with numerous patients each day will therefore inevitably impact patient 
throughput of the scanner. Other costs, as for PET tracer and hardware, will also be  
higher for D-PET compared with DCE-CT 
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6.2. Tumour visualisation by CE-CBCT 
Tumour visualisation with CE-CBCT may be attractive since CBCT is now an 
integrated and customary component of newer linear accelerators. The usefulness of 
CE-CBCT for biologically adapted radiotherapy depends, however, on how well the 
technique can be utilised for proper tumour visualisation. Tumours in certain anatomical 
sites are less separable from surrounding soft tissues in ordinary CBCT images, as 
shown for example in a recent study for 1-2 cm (T1c) breast tumours on pre-operative 
CT scans.107 This was also the case for the canine patient examined in the current 
project (paper II). Comparing pre- and post-contrast images, the mean tumour contrast 
enhancement was between 80 and 140 HU. This was not enough for satisfactory tumour 
visualisations in the post-contrast images. However, the image subtraction technique 
presented in paper II demonstrated a distinct visualisation of the tumour and was shown 
to be a feasible approach. The same procedure has at a later stage been applied for two 
other canine patients with head and neck tumours (patients B and C in Fig. 13). The 
results were in accordance with the first patient (patient A). The image subtraction 
technique may therefore be a useful tool for visualisation in biologically adapted 
radiotherapy.  
The subtraction technique has drawbacks, however, that might limit its 
applicability. Pixel differences in pre- and post-contrast images caused by statistical 
noise and patient movements between image acquisitions will be visible in the overlays. 
This may disturb interpretation of the images, even if these effects to a certain extent 
can be counteracted by applying smoothing filters and precise co-registering of pre- and 
post-contrast image sets. Further, the method has to be adapted to clinical settings by 
developing software which can be safely operated by the treatment personnel. Also, the 
image analysis information has to be interpreted and translated into correction actions. 
There are therefore some steps to be taken on the technical side to make this procedure 
applicable.  
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Figure 13. The image subtraction and overlay technique applied on three canine 
patients, A, B, and C. (Left) CT overlay. (Middle) CBCT overlay. (Right) PET/CT 
overlay. Data presented at ESTRO29, at the 2nd Norwegian Conference in Medical 
Imaging and at CERRO 2011. 
 
6.3. Adaptive strategies 
Adaptive treatment strategies based on tumour monitoring along the fractionated 
treatment course depend on reliable visualisation of the tumour and of the tumour 
changes caused by the therapy. For the case tested in paper III, the highest EUD values 
were obtained for fully adapted planning based on each of the five CE-CBCT image 
series. The advantage of such a strategy was assumed to be even larger for patients with 
more pronounced tumour positional changes relative to bone, and greater tumour 
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deformations during the treatment, than the case presented. Others have demonstrated 
large variation in the amount and rate of such positional changes and variations during 
radiotherapy, which had potential dosimetric impact when highly conformal treatment 
techniques were used.108-110 By reliable visualisation of the tumour at the treatment unit, 
such tumour position variations and deformations could potentially be detected, and an 
optimal adaptive strategy could be pursued for each patient. 
As outlined above, repeated CE-CBCT scans may not be appropriate for patients 
with certain risk factors related to injection of contrast agents. However, the use of 
nonionic contrast agents or novel, liposomal contrast agent formulations, co-
encapsulating the iohexol molecule, may in near future allow frequent CE-CBCT 
imaging at a decreased risk of nephrotoxicity.111 Development of such contrast agents 
may therefore prove to be beneficial also in radiotherapy settings. 
6.4. Dose painting 
Dose painting has been found technically feasible in several dose planning studies.9, 96, 
102, 103, 112-114 We are, however, aware of only four concluded dose painting trials; two 
FDG PET based trials on head and neck cancers and two MRI based dose escalation 
trials for prostate cancers.102, 103, 115, 116  Trials for focal dose escalation of prostate 
cancer (FLAME) and FDG PET based lung cancer dose escalation are still accruing 
patients.117, 118 
Both DPBN and level based DPBC have been found applicable, yet giving 
different results. While DPBC strives for a homogeneous dose within one or several 
defined contours, DPBN has the inherent ability of creating peak-dose regions 
according to the intensity variations of the voxels.9 The intensity variation of the voxels 
in the dose prescription matrix depends on the resolution of the diagnostic images, 
however, and the realistically obtainable image resolution for PET images has up till 
now been 4-6 mm. Whether dose painting is applicable for prescription matrices of 
higher resolution, or for dose distributions with highly dispersed high dose areas, have 
to our knowledge not been closely investigated. Paper IV and V deal with these aspects 
in order to quantify the biological effects of such a high resolution, biologically adapted 
IMRT. 
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The dose painting principle in paper IV and V was contour based (DPBC), 
splitting the dose prescription matrix up into four dose levels. Still, the cases were 
approaching DPBN prescriptions, due to the dispersed nature of the four dose 
compartments. The voxel size of the dose prescription matrix was well below both what 
is obtainable with today’s PET technology and also below obtainable accuracy in 
current, clinical target volume definitions. Paper IV showed that for this tumour model, 
reducing the MLC leaf widths from 10 down to 5 or 2.5 mm gave a considerable gain in 
biological effect, and high resolution MLCs may therefore be a prerequisite for focal 
treatment of such tumours.  However, the advantage of small leaf widths diminished 
rapidly when spatial displacement errors were introduced. This was expected, since 
target volume margins were not applied in the dose planning. Today’s clinical 
delineation and treatment accuracy may hence be of such a magnitude that the 
advantage of small leaf widths is reduced. 
In paper V the planned and delivered IMRT was evaluated by radiobiological 
measures. Compared to the prescribed treatment, the results showed highly reduced 
mean doses and biological effect for the most hypoxic regions. Dispersed, small sized 
target volumes in combination with a considerable dose escalation, as investigated in 
the present work, may therefore not be properly dose painted with the current planning 
and treatment technology. Still, level based dose painting has been demonstrated to be 
successful with other boundary conditions.21, 98 It is thus reasonable to assume that the 
spread and resolution of target subvolumes in the present tumour model, in addition to 
the large span in dose prescription levels, put restrictions on the treatment which the 
applied dose painting algorithm could not overcome. The limits for these constraints 
still remain to be determined. 
It is further shown that DBDN with a biological optimisation objective gives 
higher peak doses for regions of high prescribed doses compared to the contour-based 
approach.98, 100 Others have also demonstrated more successful dose painting with 
DPBN than DPBC.96 One would therefore expect higher EUD values with the 
application of DPBN for the applied tumour model. However, such dose planning 
options are not yet available at our institution. The same considerations apply for 
alternative treatment techniques, like VMAT, which has successfully been evaluated in 
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combination with level based DPBC.21 VMAT may thus be an option which should be 
considered for the given tumour model. 
The true biological variations of radioresistance, which for hypoxia related 
radioresistance can appear within a few tenths of a millimetre, were not mapped with 
the present tumour model.8 Dose adaptation to true radioresistance mapping is further 
far from being reached clinically, since the resolution in current PET imaging is even 
lower than for the applied tumour model. There are also issues on the treatment side, 
such as patient instability, treatment setup accuracy and dose gradient limitations of the 
IMRT, which put restrictions on the practical resolution of the resulting dose 
distribution. It has further been shown that the dose gradients in DPBN are reasonably 
congruent with the biological SUV gradients in current PET imaging.98 True 
radioresistance dose adaptation may therefore not be desirable.98 Still, the PET 
technology is evolving and TOF PET/CT scanning, giving better spatial resolution and 
improved visualisation of small uptake foci, is now possible.119 Such progress thus 
contributes to further developments in dose painting. 
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7. Conclusions 
This work revealed that assessment of early uptake patterns in tumours by D-PET and 
DCE-CT gave similar results for three canine patients studied. The contrast-
enhancement technique developed was found to be feasible both for CBCT imaging and 
for conventional CT imaging and may be useful for online/offline setup corrections. 
Fully adapted dose planning based on each CE-CBCT image series gave a delivered 
treatment closest to the prescription. Reducing the MLC leaf widths may be beneficial 
for adapted radiotherapy. Reducing the leaf width from 10 to 5 mm gave higher 
estimated tumour effect than a reduction from 5 to 2.5 mm. Accurate patient setup is, 
however, a prerequisite for achieving increased probability of cure when using 
nonuniform instead of uniform dose distributions. IMRT of the heterogeneous tumour 
model produced a sub optimal dose distribution. Still, the treatments showed high 
relative spatial accordance with the dose plan. 
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8. Further perspectives 
The present thesis is to a great extent based on case studies. Further research should 
therefore aim at including patients in clinical trials to test the validity of the results on a 
larger scale. Implementing CE-CBCT in a clinical setting is discussed above and 
presupposes a certain refinement of software applications for user-friendly handling of 
the procedures. Parallel to this it will be possible, however, to apply the technique on a 
simplified technical basis for head and neck radiotherapy patients undergoing PET/CT 
examinations. The CT part of these examinations is now routinely performed with iv 
contrast as the standard method. One additional CT pre-scan without contrast is 
therefore sufficient to supply data for the contrast enhancement technique developed. 
Such investigations will produce valuable image information from a CBCT-like clinical 
setting and can give indications whether the technique is of clinical relevance. Data 
from a pilot patient have been analysed and the results seem to be in line with the results 
from the canine treatment study (Fig. 14).  
 
   
 
Figure 14. (Left) The image subtraction and overlay technique applied on CE-CT 
images of a human head and neck patient. The contrast enhancement in large blood 
vessels is set to zero. (Right) FDG PET/CT image of the same patient. 
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Numerous studies show a significant relation between high pre-therapy SUVmax 
and reduced disease-free survival for head and neck patients.120 A relationship has 
further been shown between pre-treatment tumour vascular parameters, measured by 
DCE-MRI, and reduction in FDG metabolism after one cycle of chemotherapy for 
breast carcinoma patients.121 Here, a well developed vascular network, as measured by 
DCE-MRI, gave more effective chemotherapy, with cell kill measured by FDG-PET. 
Later studies on maximum tolerated doses for head and neck treatments have shown 
that dose escalation is possible without introducing severe toxic effects in the patients.99, 
102 These studies motivate for a clinical trial for head and neck cancer patients 
comparing dose painting based on FDG PET imaging with conventional treatment. As 
chemotherapy is given concomitantly, monitoring of vascular status with DCE-CT 
before and during treatment may give valuable information with respect to identifying 
patients not responding to therapy. Furthermore, as DCE-CT vascular status also may 
be linked to hypoxia, this imaging modality could play a role in predicting radiation 
response. Alternatively, the combined DCE-CT and static PET examination may be 
replaced by a D-PET scan only. CE-CBCT, as discussed above, would also be possible 
within the limits set by kidney tolerance. Such studies represent a follow up of the 
techniques presented in the current work and may give information on the relation 
between dose escalation effects and metabolic and vascular parameters.  
Treatment planning algorithms for VMAT will shortly be introduced at our 
hospital. This will give us the opportunity to repeat the dosimetric investigation of dose 
painting by the use of another treatment technique. Planning systems offering DPBN 
and biological optimisation objectives should also be searched for and tested, and 
studies involving such technology may be a future option. 
  55 
Bibliography 
1. Tredan O, Galmarini CM, Patel K, et al. Drug resistance and the solid tumor 
microenvironment. Journal of the National Cancer Institute 2007;99:1441-1454. 
2. Vaupel P. Tumor microenvironmental physiology and its implications for 
radiation oncology. Seminars in Radiation Oncology 2004;14:198-206. 
3. Laskar SG, Agarwal JP, Srinivas C, et al. Radiotherapeutic management of 
locally advanced head and neck cancer. Expert Review of Anticancer Therapy 
2006;6:405-417. 
4. Chao KSC, Ozyigit G, Tran BN, et al. Patterns of failure in patients receiving 
definitive and postoperative IMRT for head-and-neck cancer. International 
Journal of Radiation Oncology Biology Physics 2003;55:312-321. 
5. Cellini N, Morganti AG, Mattiucci GC, et al. Analysis of intraprostatic failures 
in patients treated with hormonal therapy and radiotherapy: Implications for 
conformal therapy planning. International Journal of Radiation Oncology 
Biology Physics 2002;53:595-599. 
6. Ling CC, Humm J, Larson S, et al. Towards multidimensional radiotherapy 
(MD-CRT): Biological imaging and biological conformality. International 
Journal of Radiation Oncology Biology Physics 2000;47:551-560. 
7. Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by 
numbers. Lancet Oncology 2005;6:112-117. 
8. Chao KSC, Bosch WR, Mutic S, et al. A novel approach to overcome hypoxic 
tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. 
International Journal of Radiation Oncology Biology Physics 2001;49:1171-
1182. 
9. Vanderstraeten B, Duthoy W, De Gersem W, et al. [F-18]fluoro-deoxy-glucose 
positron emission tomography ([F-18]FDG-PET) voxel intensity-based 
intensity-modulated radiation therapy (IMRT) for head and neck cancer. 
Radiotherapy and Oncology 2006;79:249-258. 
10. Sovik A, Malinen E, Bruland OS, et al. Optimization of tumour control 
probability in hypoxic tumours by radiation dose redistribution: a modelling 
study. Physics in Medicine and Biology 2007;52:499-513. 
11. Stavreva NA, Stavrev PV, Round WH. A mathematical approach to optimizing 
the radiation dose distribution in heterogeneous tumours. Acta Oncologica 
1996;35:727-732. 
12. Brahme A, Agren AK. Optimal Dose Distribution for Eradication of 
Heterogeneous Tumors. Acta Oncologica 1987;26:377-385. 
13. Brahme A. Biologically optimized 3-dimensional in vivo predictive assay-based 
radiation therapy using positron emission tomography-computerized 
tomography Imaging. Acta Oncologica 2003;42:123-136. 
14. Popple RA, Ove R, Shen S. Tumor control probability for selective boosting of 
hypoxic subvolumes, including the effect of reoxygenation. International 
Journal of Radiation Oncology Biology Physics 2002;54:921-927. 
15. Just what is Molecular Imaging?: Center for Molecular Imaging Innovation and 
Translation. 
  56 
16. ClinicalTrials.gov. Functional Imaging of Tumor and Normal Tissue (FITT). 
2011. 
17. Glunde K, Pathak AP, Bhujwalla ZM. Molecular-functional imaging of cancer: 
to image and imagine. Trends in Molecular Medicine 2007;13:287-297. 
18. Malinen E. Spatiotemporal analysis of tumor uptake patterns in dynamic 
18FDG-PET and dynamic contrast enhanced CT. 2011. 
19. Sovik A, Malinen E, Olsen DR. Strategies for Biologic Image-Guided Dose 
Escalation: a Review. International Journal of Radiation Oncology Biology 
Physics 2009;73:650-658. 
20. Thorwarth D, Alber M. Implementation of hypoxia imaging into treatment 
planning and delivery. Radiotherapy and Oncology 2010;97:172-175. 
21. Korreman SS, Ulrich S, Bowen S, et al. Feasibility of dose painting using 
volumetric modulated arc optimization and delivery. Acta Oncologica 
2010;49:964-971. 
22. U.S. National Institutes of Health, National Cancer Institute (www.cancer.gov). 
23. Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic 
strategies. Molecular Medicine Today 2000;6:157-162. 
24. Sporn MB. The war on cancer. Lancet 1996;347:1377-1381. 
25. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. 
26. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell 
2011;144:646-674. 
27. American Cancer Sosiety Inc. (www.cancer.org). 
28. Radiotherapy in Norway: Norwegian Radiation Protection Authority; 2010. 
29. Cancer in Norway 2009: Cancer Registry of Norway, Institute of population-
based cancer research; 2011. 
30. Miles KA. Tumour angiogenesis and its relation to contrast enhancement on 
computed tomography: a review. European Journal of Radiology 1999;30:198-
205. 
31. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 
2004;9:10-17. 
32. Vaupel P, Mayer A. Hypoxia and anemia: effects on tumor biology and 
treatment resistance. Transfusion Clinique Et Biologique 2005;12:5-10. 
33. Wilson GD. Cell kinetics. Clinical Oncology 2007;19:370-384. 
34. Paoloni M, Khanna C. Science and society - Translation of new cancer 
treatments from pet dogs to humans. Nature Reviews Cancer 2008;8:147-156. 
35. Bernier J, Hall EJ, Giaccia A. Timeline - Radiation oncology: a century of 
achievements. Nature Reviews Cancer 2004;4:737-U715. 
36. Gray LH, Conger AD, Ebert M, et al. The Concentration of Oxygen Dissolved 
in Tissues at the Time of Irradiation as a Factor in Radiotherapy. British Journal 
of Radiology 1953;26:638-648. 
37. Steel GG. Basic Clinical Radiobiology. Third edition. London: Hodder Arnold 
Publication 2002. 
38. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated 
radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006;368:843-
854. 
39. Bussink J, van der Kogel AJ, Kaanders J. Activation of the PI3-K/AKT pathway 
and implications for radioresistance mechanisms in head and neck cancer. 
Lancet Oncology 2008;9:288-296. 
  57 
40. Dutreix M, Cosset JM, Sun JS. Molecular therapy in support to radiotherapy. 
Mutation Research-Reviews in Mutation Research 2010;704:182-189. 
41. Harima Y, Sawada S, Miyazaki Y, et al. Expression of Ku80 in cervical cancer 
correlates with response to radiotherapy and survival. Am J Clin Oncol 
2003;26:e80-85. 
42. Santucci MA, Barbieri E, Frezza G, et al. Radiation-induced Gadd45 expression 
correlates with clinical response to radiotherapy of cervical carcinoma. 
International Journal of Radiation Oncology Biology Physics 2000;46:411-416. 
43. Wilson CR, Davidson SE, Margison GP, et al. Expression of Ku70 correlates 
with survival in carcinoma of the cervix. British Journal of Cancer 
2000;83:1702-1706. 
44. Joiner M, van der Kogel A. Basic Clinical Radiobiology. Fourth edition. Hodder 
Arnold 2009. 
45. West CML, Davidson SE, Roberts SA, et al. The independence of intrinsic 
radiosensitivity as a prognostic factor for patient response to radiotherapy of 
carcinoma of the cervix. British Journal of Cancer 1997;76:1184-1190. 
46. Bjork-Eriksson T, West C, Karlsson E, et al. Tumor radiosensitivity (SF2) is a 
prognostic factor for local control in head and neck cancers. International 
Journal of Radiation Oncology Biology Physics 2000;46:13-19. 
47. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and 
radiotherapy for organ preservation in advanced laryngeal cancer. New England 
Journal of Medicine 2003;349:2091-2098. 
48. Maciejewski B, Withers HR, Taylor JMG, et al. Dose Fractionation and 
Regeneration in Radiotherapy for Cancer of the Oral Cavity and Oropharynx - 
Tumor Dose-Response and Repopulation. International Journal of Radiation 
Oncology Biology Physics 1989;16:831-843. 
49. Withers HR, Taylor JMG, Maciejewski B. The Hazard of Accelerated Tumor 
Clonogen Repopulation During Radiotherapy. Acta Oncologica 1988;27:131-
146. 
50. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: An important 
cause of treatment failure. Nature Reviews Cancer 2005;5:516-525. 
51. Zahra MA, Hollingsworth KG, Sala E, et al. Dynamic contrast-enhanced MRI as 
a predictor of tumour response to radiotherapy. Lancet Oncology 2007;8:63-74. 
52. Nordsmark M, Overgaard J. Tumor hypoxia is independent of hemoglobin and 
prognostic for loco-regional tumor control after primary radiotherapy in 
advanced head and neck cancer. Acta Oncol 2004;43:396-403. 
53. Lyng H, Sundfor K, Trope C, et al. Disease control of uterine cervical cancer: 
relationships to tumor oxygen tension, vascular density, cell density, and 
frequency of mitosis and apoptosis measured before treatment and during 
radiotherapy. Clin Cancer Res 2000;6:1104-1112. 
54. Overgaard J, Eriksen JG, Nordsmark M, et al. Plasma osteopontin, hypoxia, and 
response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck 
cancer: results from the DAHANCA 5 randomised double-blind placebo-
controlled trial. Lancet Oncol 2005;6:757-764. 
55. Nahum AE, Sanchez-Nieto B. Tumour control probability modelling: Basic 
principles and applications in treatment planning. Physica Medica 2001;17:13-
23. 
  58 
56. Webb S, Nahum AE. A Model for Calculating Tumor-Control Probability in 
Radiotherapy Including the Effects of Inhomogeneous Distributions of Dose and 
Clonogenic Cell-Density. Physics in Medicine and Biology 1993;38:653-666. 
57. Sanchez-Nieto B, Nahum AE. The delta-TCP concept: a clinically useful 
measure of tumor control probability. Int J Radiat Oncol Biol Phys 
1999;44:369-380. 
58. Sovik A, Ovrum J, Olsen DR, et al. On the parameter describing the generalised 
equivalent uniform dose (gEUD) for tumours. Physica Medica 2007;23:100-
106. 
59. Beckmann EC. CT scanning the early days. British Journal of Radiology 
2006;79:5-8. 
60. Mansfield P, Maudsley AA. Medical Imaging by Nmr. British Journal of 
Radiology 1977;50:188-194. 
61. Terpogossian MM, Phelps ME, Hoffman EJ, et al. Positron-Emission Transaxial 
Tomograph for Nuclear Imaging (Pett). Radiology 1975;114:89-98. 
62. Ido T, Wan CN, Casella V, et al. Labeled 2-Deoxy-D-Glucose Analogs - F-18-
Labeled 2-Deoxy-2-Fluoro-D-Glucose, 2-Deoxy-2-Fluoro-D-Mannose and C-
14-2-Deoxy-2-Fluoro-D-Glucose. Journal of Labelled Compounds & 
Radiopharmaceuticals 1978;14:175-183. 
63. Townsend DW. Dual-modality imaging: Combining anatomy and function. 
Journal of Nuclear Medicine 2008;49:938-955. 
64. Bussink J, Kaanders J, van der Graaf WTA, et al. PET-CT for radiotherapy 
treatment planning and response monitoring in solid tumors. Nature Reviews 
Clinical Oncology 2011;8:233-242. 
65. Khan FM. The Physics of Radiation Therapy. 1984. 
66. Knoos T, Nilsson M, Ahlgren L. A Method for Conversion of Hounsfield 
Number to Electron-Density and Prediction of Macroscopic Pair Production 
Cross-Sections. Radiotherapy and Oncology 1986;5:337-345. 
67. Nucletron BV. Oncentra External Beam v4.0, Physics and algoritms. 
68. Rogalla P, Kloeters C, Hein PA. CT Technology Overview: 64-Slice and 
Beyond. Radiologic Clinics of North America 2009;47:1-+. 
69. Lee TY, Purdie TG, Stewart E. CT imaging of angiogenesis. Quarterly Journal 
of Nuclear Medicine 2003;47:171-187. 
70. Dowsett DJ, Kenny PA, Johnston RE. The Physics of Diagnostic Imaging, 
Second edition. Oxford University Press Inc., New York 2006. 
71. Cooper RA, Carrington BM, Loncasters JA, et al. Tumour oxygenation levels 
correlate with dynamic contrast-enhanced magnetic resonance imaging 
parameters in carcinoma of the cervix. Radiotherapy and Oncology 2000;57:53-
59. 
72. Patton JA, Townsend DW, Hutton BF. Hybrid Imaging Technology: From 
Dreams and Vision to Clinical Devices. Seminars in Nuclear Medicine 
2009;39:247-263. 
73. Apisarnthanarax S, Chao KSC. Current Imaging paradigms in radiation 
oncology. Radiation Research 2005;163:1-25. 
74. Heron DE, Smith RP, Andrade RS. Advances in image-guided radiation therapy 
- The role of PET-CT. Medical Dosimetry 2006;31:3-11. 
  59 
75. Mankoff DA, Eary JF, Link JM, et al. Tumor-specific positron emission 
tomography Imaging in patients: [F-18) fluorodeoxyglucose and beyond. 
Clinical Cancer Research 2007;13:3460-3469. 
76. Pugachev A, Ruan S, Carlin S, et al. Dependence of FDG uptake on tumor 
microenvironment. International Journal of Radiation Oncology Biology 
Physics 2005;62:545-553. 
77. Christian N, Deheneffe S, Bol A, et al. Is F-18-FDG a surrogate tracer to 
measure tumor hypoxia? Comparison with the hypoxic tracer C-14-EF3 in 
animal tumor models. Radiotherapy and Oncology 2010;97:183-188. 
78. Warburg O. Respiratory Impairment in Cancer Cells. Science 1956;124:269-
270. 
79. Busk M, Horsman MR, Jakobsen S, et al. Cellular uptake of PET tracers of 
glucose metabolism and hypoxia and their linkage. European Journal of Nuclear 
Medicine and Molecular Imaging 2008;35:2294-2303. 
80. Thie JA. Understanding the standardized uptake value, its methods, and 
implications for usage. Journal of Nuclear Medicine 2004;45:1431-1434. 
81. Keyes JW. Suv - Standard Uptake or Silly Useless Value. Journal of Nuclear 
Medicine 1995;36:1836-1839. 
82. Marton L, Marton C. Advances in electronics and electron physics. . Academic 
Press, Inc. 1980;50. 
83. Thwaites DI, Tuohy JB. Back to the future: the history and development of the 
clinical linear accelerator. Physics in Medicine and Biology 2006;51:R343-
R362. 
84. Verellen D, De Ridder M, Storme G. A (short) history of image-guided 
radiotherapy. Radiotherapy and Oncology 2008;86:4-13. 
85. Rosenman J. Incorporating functional imaging information into radiation 
treatment. Seminars in Radiation Oncology 2001;11:83-92. 
86. www.radiologyinfo.org. 
87. Galvin JM, Ezzell G, Eisbrauch A, et al. Implementing IMRT in clinical 
practice: A joint document of the American Society for Therapeutic Radiology 
and Oncology and the American Association of Physicists in Medicine. 
International Journal of Radiation Oncology Biology Physics 2004;58:1616-
1634. 
88. Galvin JM, De Neve W. Intensity modulating and other radiation therapy 
devices for dose painting. Journal of Clinical Oncology 2007;25:924-930. 
89. Brahme A, Roos JE, Lax I. Solution of an Integral-Equation Encountered in 
Rotation Therapy. Physics in Medicine and Biology 1982;27:1221-1229. 
90. Censor Y, Altschuler MD, Powlis WD. A Computational Solution of the Inverse 
Problem in Radiation-Therapy Treatment Planning. Applied Mathematics and 
Computation 1988;25:57-87. 
91. Nucletron BV. Oncentra External Beam v4.0 User Manual. Ref 170.730. 
92. Tome WA, Fowler JF. Selective boosting of tumor subvolumes. International 
Journal of Radiation Oncology Biology Physics 2000;48:593-599. 
93. Chapman JD, Schneider RF, Urbain JL, et al. Single-photon emission computed 
tomography and positron-emission tomography assays for tissue oxygenation. 
Seminars in Radiation Oncology 2001;11:47-57. 
94. Tanderup K, Olsen DR, Grau C. Dose painting: Art or science? Radiotherapy 
and Oncology 2006;79:245-248. 
  60 
95. Alber M, Paulsen F, Eschmann SM, et al. On biologically conformal boost dose 
optimization. Physics in Medicine and Biology 2003;48:N31-N35. 
96. Thorwarth D, Eschmann SM, Paulsen F, et al. Hypoxia dose painting by 
numbers: A planning study. International Journal of Radiation Oncology 
Biology Physics 2007;68:291-300. 
97. Sovik A, Malinen E, Skogmo HK, et al. Radiotherapy adapted to spatial and 
temporal variability in tumor hypoxia. International Journal of Radiation 
Oncology Biology Physics 2007;68:1496-1504. 
98. Meijer G, Steenhuijsen J, Bal M, et al. Dose painting by contours versus dose 
painting by numbers for stage II/III lung cancer: Practical implications of using 
a broad or sharp brush. Radiother Oncol 2011;100:396-401. 
99. Madani I, Duprez F, Boterberg T, et al. Maximum tolerated dose in a phase I 
trial on adaptive dose painting by numbers for head and neck cancer. Radiother 
Oncol 2011;2011:8. 
100. Vanderstraeten B, De Gersem W, Duthoy W, et al. Implementation of 
biologically conformal radiation therapy (BCRT) in an algorithmic 
segmentation-based inverse planning approach. Physics in Medicine and Biology 
2006;51:N277-N286. 
101. Pijls-Johannesma M, van Mastrigt G, Hahn SM, et al. A systematic 
methodology review of phase I radiation dose escalation trials. Radiotherapy 
and Oncology 2010;95:135-141. 
102. Madani I, Duthoy W, Derie C, et al. Positron emission tomography-guided, 
focal-dose escalation using intensity-modulated radiotherapy for head and neck 
cancer. International Journal of Radiation Oncology Biology Physics 
2007;68:126-135. 
103. Duprez F, De Neve W, De Gersem W, et al. Adaptive Dose Painting by 
Numbers for Head-and-Neck Cancer. International Journal of Radiation 
Oncology Biology Physics 2011;80:1045-1055. 
104. Busk M, Horsman MR, Overgaard J. Resolution in PET hypoxia imaging: Voxel 
size matters. Acta Oncologica 2008;47:1201-1210. 
105. Dawson LA, Jaffray DA. Advances in image-guided radiation therapy. Journal 
of Clinical Oncology 2007;25:938-946. 
106. Cao MS, Liang YR, Shen CY, et al. Developing DCE-CT to Quantify Intra-
Tumor Heterogeneity in Breast Tumors With Differing Angiogenic Phenotype. 
Ieee Transactions on Medical Imaging 2009;28:861-871. 
107. Boersma LJ, Hanbeukers B, Boetes C, et al. Is contrast enhancement required to 
visualize a known breast tumor in a pre-operative CT scan? Radiotherapy and 
Oncology 2011;100:271-275. 
108. Knap MM, Hoffmann L, Nordsmark M, et al. Daily cone-beam computed 
tomography used to determine tumour shrinkage and localisation in lung cancer 
patients. Acta Oncologica 2010;49:1077-1084. 
109. Barker JL, Garden AS, Ang KK, et al. Quantification of volumetric and 
geometric changes occurring during fractionated radiotherapy for head-and-neck 
cancer using an integrated CT/linear accelerator system. International Journal of 
Radiation Oncology Biology Physics 2004;59:960-970. 
110. Geets X, Tomsej M, Lee JA, et al. Adaptive biological image-guided IMRT 
with anatomic and functional imaging in pharyngo-laryngeal tumors: Impact on 
  61 
target volume delineation and dose distribution using helical tomotherapy. 
Radiotherapy and Oncology 2007;85:105-115. 
111. Zheng JZ, Liu JB, Dunne M, et al. In vivo performance of a liposomal vascular 
contrast agent for CT and MR-based image guidance applications. 
Pharmaceutical Research 2007;24:1193-1201. 
112. Thorwarth D, Geets X, Paiusco M. Physical radiotherapy treatment planning 
based on functional PET/CT data. Radiotherapy and Oncology 2010;96:317-
324. 
113. Korreman S, Medin J, Kjaer-Kristoffersen F. Dosimetric verification of 
RapidArc treatment delivery. Acta Oncologica 2009;48:185-191. 
114. Schwartz DL, Ford EC, Rajendran J, et al. FDG-PET/CT-guided intensity 
modulated head and neck radiotherapy: A pilot investigation. Head and Neck-
Journal for the Sciences and Specialties of the Head and Neck 2005;27:478-487. 
115. Fonteyne V, Villeirs G, Speleers B, et al. Intensity-modulated radiotherapy as 
primary therapy for prostate cancer: Report on acute toxicity after dose 
escalation with simultaneous integrated boost to intraprostatic lesion. 
International Journal of Radiation Oncology Biology Physics 2008;72:799-807. 
116. Singh AK, Guion P, Sears-Crouse N, et al. Simultaneous integrated boost of 
biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with 
IMRT: early results of a phase I NCI study. Radiation Oncology 2007;2. 
117. ClinicalTrials.gov. FLAME: Investigate the Benefit of a Focal Lesion Ablative 
Microboost in Prostate Cancer. 
118. ClinicalTrials.gov. Dose Escalation by Boosting Radiation Dose Within the 
Primary Tumor on the Basis of a Pre-treatment FDG-PET-CT Scan in Stage IB, 
II and III NSCLC: a Randomized Phase II Trial (PET Boost). 
119. Conti M. Focus on time-of-flight PET: the benefits of improved time resolution. 
European Journal of Nuclear Medicine and Molecular Imaging;38:1147-1157. 
120. Machtay M, Natwa M, Andrel J, et al. Pretreatment FDG-PET standardized 
uptake value as a prognostic factor for outcome in head and neck cancer. Head 
Neck 2009;31:195-201. 
121. Semple SIK, Staff RT, Heys SD, et al. Baseline MRI delivery characteristics 
predict change in invasive ductal breast carcinoma PET metabolism as a result 
of primary chemotherapy administration. Annals of Oncology 2006;17:1393-
1398. 
 

Paper I: 
Malinen E, Rødal J, Knudtsen IS, Søvik Å, Skogmo HK.  
Spatiotemporal analysis of tumor uptake patterns in dynamic 18FDG-PET and dynamic 
contrast enhanced CT.  
Acta Oncologica 2011;50:873-882. Paper I
 
Is not included due to copyright 

Paper II: 
Rødal J, Søvik Å, Skogmo HK, Knudtsen IS, Malinen E. 
Feasibility of contrast-enhanced cone-beam CT for target localization and treatment 
monitoring.  
Radiotherapy and Oncology 200;97:521-52 
Paper II

Target deﬁnition
Feasibility of contrast-enhanced cone-beam CT for target localization
and treatment monitoring
Jan Rødal a,b,*, Åste Søvik c,d, Hege Kippenes Skogmo d, Ingerid Skjei Knudtsen e, Eirik Malinen a
aDepartment of Medical Physics, The Norwegian Radium Hospital, Oslo University Hospital, Norway; bDepartment of Physics, The Norwegian University of Science and
Technology, Trondheim, Norway; cDepartment of Radiation Biology, The Norwegian Radium Hospital, Oslo University Hospital, Norway; dDepartment of Companion Animal
Clinical Sciences, Norwegian School of Veterinary Science, Oslo, Norway; e Interventional Centre, Oslo University Hospital, Norway
a r t i c l e i n f o
Article history:
Received 19 March 2010
Received in revised form 14 June 2010
Accepted 3 July 2010
Keywords:
Cone-beam CT
Contrast agent
Image guided radiotherapy
a b s t r a c t
A dog with a spontaneous maxillary tumour was given 40 Gy of fractionated radiotherapy. At ﬁve out of
10 fractions cone-beam CT (CBCT) imaging before and after administration of an iodinated contrast agent
were performed. Contrast enhancement maps were overlaid on the pre-contrast CBCT images. The
tumour was clearly visualized in the images thus produced.
 2010 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 97 (2010) 521–524
Modern linear accelerators with cone-beam CT (CBCT) systems
enable volumetric imaging of the patient at the treatment site [1].
Use of bony anatomy, ﬁducial markers and soft tissue tumours and
organs is widely explored as markers for image guided radiother-
apy (IGRT) [2–4] and planning [5]. However, using the tumour it-
self as a registration object is not straightforward. The tumour
boundaries may not be visually separable from surrounding soft
tissue in an ordinary CBCT image, as reported for head and neck tu-
mours, tumours in the thorax and upper abdomen and in the pelvic
region [6,7]. The tumour may also migrate or deform during radio-
therapy [8]. Thus, there is a need for methods that improve the soft
tissue contrast in CBCT images.
Contrast-enhanced CT with iodinated contrast agents is a com-
mon imaging procedure for radiotherapy planning, as soft tissue
tumours may show increased enhancement compared to normal
tissue due to increased perfusion and blood vessel permeability
caused by tumour angiogenesis [9]. The usefulness of contrast-en-
hanced CBCT imaging has been suggested in the literature [6]. If
feasible, such imaging may not only be useful for online/ofﬂine pa-
tient set-up corrections, but also for monitoring biological and spa-
tial changes of the tumour during treatment [10]. In addition,
tumour boosting may be facilitated.
To our knowledge only one group has published results on con-
trast media-assisted visualization with CBCT [11,12]. In these stud-
ies, brain and liver metastases were visualized directly in images
acquired after contrast injection. In the current work a different ap-
proach was taken, where both pre- and post-contrast images were
acquired. Thus, the net contrast enhancement could be obtained
voxel by voxel. Overlaid on standard CBCT images this may give
improved tumour visualization. Additionally, as contrast-enhanced
CBCT imaging was performed during the course of fractionated
radiotherapy, a means of monitoring changes in tumour enhance-
ment was provided.
Methods and materials
A nine years old female Border collie with a body weight of
24 kg presented with a spontaneous, 14 cm3 plasma cell tumour
in the right maxilla. The imaging and treatment described below
was approved by the National Ethics Committee and a written in-
formed consent was obtained from the dog’s owner. Before imag-
ing and treatment, the patient was pre-medicated with
detomidin 5 lg/kg iv (Domitor vet., Orion, Turku, Finland) and
butorfanol 0.05 mg/kg iv (Dolorex vet., Intervet, Boxmeer, the
Netherlands). Anaesthesia was induced with propofol 2.0 mg/kg
iv (PropoVet, Abbot, Illinois, USA) and tracheal intubation was per-
formed. Anaesthesia was maintained with continuous rate infusion
of propofol at a dose rate of 10 mg/kg/h iv. The patient was placed
in prone position on a vacuum cushion (VacFix, Par Scientiﬁc A/S,
Odense Denmark) in a polymethyl methacrylate (PMMA) case with
open front and tail walls. The upper jaw was ﬁxated by a dental
form anchored to the PMMA bin.
Three days before start of radiotherapy a PET/CT scan of the dog
was obtained at a Biograph16 scanner (Siemens AG, Munich, Ger-
many). The PET/CT images were used as basis for treatment plan-
ning (see below). Also, a 10 min dynamic contrast-enhanced CT
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scan over the central part of tumour was obtained at the same
scanner. The contrast uptake in the tumour reached a plateau at
about one minute post-injection (PI) (data not shown). The con-
trast agent was Omnipaque (Iohexol, 300 mg/ml, GE Healthcare,
Oslo, Norway), administered intravenously at a dose of 600 mg/
kg by means of a power injector.
IMRT was planned using the KonRad inverse treatment plan-
ning system (v. 2.2.18, Siemens Medical Solutions, Germany) with
ﬁve ﬁelds, 6 MV photon energy and a dose of 40 Gy over 10 frac-
tions. The patient was treated with curative intent at an Elekta
Synergy linear accelerator (Elekta AB, Stockholm, Sweden),
equipped with a CBCT system (XVI).
Standard CBCT imaging was performed at each treatment ses-
sion, and thepatient set-upwas correctedbyautomaticbonematch-
ing to the reference CT images. Contrast-enhanced CBCT imaging
with Omnipaque 300 mg/ml at a dose of 600 mg/kg was performed
at ﬁve of the treatment sessions (Nos. 1, 3, 5, 7 and 10). At these ses-
sions a CBCT scan was taken immediately before manual contrast
injection, and a second scan was started one minute PI. No reposi-
tioning was permitted between pre- and post-contrast CBCT scans.
Axial CBCT images were reconstructed in the XVI system from
the volumetric uptakes. The reconstructed slice thickness was
1 mm and the image size 512  512 pixels with pixel size 1 mm.
The images were analyzed using custom made software in IDL
(ITT Visual Information Solutions, Boulder, USA). Brieﬂy, the pre-
contrast images were subtracted from the post-contrast images.
As contrast was injected manually, variations between fractions
in injection time and injected volume could be an issue. Indeed,
some contrast was spilled at one session (fraction 7). To correct
for such irregularities the subtraction images were normalized
according to normal tissue enhancement at the ﬁrst session. The
subtraction images were scaled using a window level of 100
Hounsﬁeld units (HU) and a window width of 100 HU. The result-
ing images were overlaid on the pre-contrast CBCT images. A ‘red
temperature’ colour gradient was used for displaying the enhance-
ment image in the overlay. The same procedure was performed for
the contrast-enhanced pre-treatment conventional CT images,
with a window level/width setting of 90/85 HU.
Treatment monitoring was tentatively performed by calculating
the mean contrast enhancement in the tumour at each session. A
region of interest (ROI) for scoring the enhancement was deﬁned
inside the tumour in pre-treatment CBCT images, with a few pixels
margin to the tumour border. The same ROI was used for all ﬁve
sessions where contrast-enhanced CBCT was performed.
Results
The maxillary tumour was clearly presented in the contrast-en-
hanced overlay CT and CBCT images. A comparison of conventional
CT, CBCT and PET/CT overlays is shown in Fig. 1. The tumour extent
and orientation appeared very similar in the respective images.
Using contrast-enhanced CBCT the tumour was clearly discrimi-
nated throughout the fractionated treatment (Fig. 2).
A slight increase in tumour enhancement during the treatment
may be seen and the mean contrast enhancement in the tumour
ROI was calculated. Following ﬁrst order linear regression, a signif-
icant (P < 0.01) increase in contrast enhancement of 5.2 HU per
treatment fraction was found. The standard deviation in tumour
contrast enhancement (indicating intra tumour heterogeneity)
varied from 29 to 46 HU between the fractions.
Discussion
Angiogenesis is essential for tumour growth and alters contrast
enhancement during CT [9]. Contrast-enhanced CT is thus a modal-
ity which may be a marker for tumour tissue, as is the case for
FDG-PET [13]. The present work aimed at exploring contrast-en-
hanced CBCT for highlighting tumour tissue. For the actual canine
patient, the tumour was clearly discriminated from its surround-
ings using both contrast-enhanced CT, FDG-PET and contrast-en-
hanced CBCT. Therefore, contrast-enhanced CBCT may be used to
identify the tumour position during treatment, which may be uti-
lized separately or in combination with bony anatomy registering.
The basis for such tumour tissue matching should be pre-treat-
ment contrast-enhanced CT or contrast-enhanced MR images, pro-
cessed with the same procedure to establish reference tumour
shape and size. The method could be particularly useful when
treating extracranial lesions where the spatial relation between
the tumour region and superﬁcial skin markers or bony anatomy
is weakly correlated [14,15].
Another utilization of contrast-enhanced CBCT is to detect spa-
tial or functional tumour changes along the treatment course with-
out taking the patient through additional CT or MRI surveys. The
location, shape and size of tumours have been found to change sig-
niﬁcantly during the treatment course due to tumour shrinkage,
weight loss and other factors [8,16,17]. Spatial changes can poten-
tially be assessed by extracting the enhanced volume, as shown in
the current work. Functional changes can be revealed by analyzing
the degree of enhancement within the tumour, which indicate
radiation-induced changes in tumour functionality. This was dem-
onstrated in the present case, where increased contrast enhance-
ment during the treatment course was found.
The cost of obtaining improved spatial and functional informa-
tion is an additional contrast-enhanced CBCT scan at selected
treatment sessions. This has drawbacks, such as prolonged treat-
ment sessions, injection of contrast agent and increased X-ray dose
to the patient. These aspects must be considered when adapting
the technique to human patients. In particular, contrast-induced
nephropathy (CIN) is a matter of great concern, and diabetes, re-
duced renal function and old age are among the risk factors [18].
CT contrast can also interact with certain drugs [18]. Tumour
boosting based on contrast-enhanced CBCT once or twice a week
might provide a high local control rate, as indicated in our previous
work employing biologically adapted treatment planning [19].
However, the risk of CIN and other adverse reactions limit the
number of contrast-enhanced CBCT sessions, and frequent con-
trast-enhanced CBCT imaging might be controversial. Possible ad-
verse effects of repeated administration of contrast media were
addressed in a study investigating a novel CT/MRI contrast agent
of liposomes co-encapsulating iohexol and gadoteridol [20]. The
novel formulation may provide long-lasting contrast enhancement
in the tumour with a decreased risk of toxicity. In any case, clinical
trials employing serial contrast-enhanced imaging (with estab-
lished or novel contrast media) must include examinations aimed
Fig. 1. Left: Conventional CT with contrast enhancement overlay. Middle: CBCT
with contrast enhancement overlay. Right: Conventional CT with FDG-PET overlay.
High uptake/enhancement is indicated by bright colours. The CT and PET/CT images
are taken three days before treatment start, the CBCT image is taken prior to the
ﬁrst treatment.
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at revealing contraindications, in addition to regular follow-up of
acute and long-term side effects.
In a clinical setting, injecting the contrast mediumwith a power
injector would be preferred in favour of a manual procedure, as
was used in the current work. A power injector ensures reduced
injection time and more reproducible timing of the contrast
administration. This may reduce the need for normalizing the
images, which was done here due to possible variations in contrast
administration throughout the course of treatment.
In the present case the tumour was signiﬁcantly enhanced com-
pared to the surrounding normal tissues (Figs. 1 and 2). However,
normal tissue uptake and statistical noise from the XVI system are
also visible in the overlay images. The noise may be reduced by
applying a smoothing ﬁlter, which should be optimized against
Fig. 2. Reconstructed CBCT images in three planes with contrast enhancement overlay at ﬁve treatment fractions. High uptake/enhancement is indicated by bright colours.
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the corresponding degradation of the tumour signal. Also, the sub-
traction procedure (pre-contrast from post-contrast) for producing
the enhancement image is sensitive to shift errors, creating edge
artefacts in the overlay images. This can be seen in the images in
Fig. 2 as enhancements along the rim of bony structures. Such arte-
facts could arise even with our sedated patient due to minor spatial
disturbances, possibly induced by the contrast injection. For a hu-
man, non-sedated patient this will be even more pertinent, where
patient motion in the order of millimetres may occur. Provided no
internal tumour movement between pre- and post-contrast CBCT
however, precise coregistration of the image sets can reduce or
eliminate these artefacts. The coregistration can be done using
bony anatomy or ﬁducial markers [21] close to the tumour in the
pre- and post-contrast data sets, thereby generating translation
and rotation parameters to adjust the image sets. This technique
is well established in today’s commercial cone-beam systems and
could be implemented in the current application as well.
In contrast to conventional CT, where the gantry rotation time is
in the order of one second, the duration of the currently used CBCT
scan is typically one minute. The underlying contrast kinetics for
the CBCT images will therefore be averaged over this scan time.
The conventional CT images in Fig. 1 were derived 2 min PI, and
correspond approximately to the situation at the end of the CBCT
scan. A complete resemblance between images produced by the
two CT modalities may not be obtained, however, due to the differ-
ences in scan time, detector and beam technologies and recon-
struction algorithms. Still, the tumour appeared qualitatively
congruent in the images presented in Fig. 1.
In conclusion, this work showed that contrast-enhanced CBCT is
feasible and may prove valuable for radiation oncology. The meth-
od is clinically relevant, but reﬁnement and further research are re-
quired to make the procedure clinically applicable.
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